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Liver Transplantation: successes and challenges 
On the first of March 1963, Dr. Starzl and associates performed the first liver 
transplantation in human at the University of Colorado.1 Despite the 
extensive and highly successful four-year laboratory experience with dogs, 
Starzl’s team failed this initial clinical attempt. It took another 4 years before 
the first recorded success in the history of human liver transplantation was 
realized. On July 23rd, 1967, a 1.5 years old girl with primary hepatocellular 
carcinoma underwent a liver transplantation and lived for 13 months before 
dying from diffuse metastases. Three decades later, more than 60,000 liver 
transplantations have been performed worldwide,2 which has indeed 
revolutionized the care for patients with end-stage liver disease: patients, who 
otherwise were doomed to die within months to years, now have the 
opportunity for extended survival with excellent quality of life after 
transplantation.3 Around 80 to 90% of the patients who undergo liver 
transplantation today are expected to be able to survive for more than a year, 
and most centres report a five-year survival rate above 70%.4-6 The drastically 
improved survival is mainly attributed to the development of effective 
immunosuppression agents, especially the introduction of cyclosporine and 
tacrolimus,7 to the use of better solutions for graft preservation8, 9 and to 
advances in anaesthetic and surgical techniques. Nowadays, liver 
transplantation is indicated for acute or chronic liver failure from more than 
sixty different diseases, amongst which cholestatic disorders, chronic 
hepatitis, alcoholic liver disease, metabolic diseases, fulminant hepatic failure 
and hepatocellular carcinoma are the most frequent indications.10 The age of 
the patients ranges from the first week of life to adults over 75 years of age.11, 
12  
Despite the recorded successes of liver transplantation, the procedure still 
faces potential complications. Poor immediate graft function and infection 
are the major causes of graft and patients loss early after transplantation.13, 14 
Although immunosuppression can safely be withdrawn in about 20% of the 
recipients,15 the majority of the long-term survivors requires life-long use of 
those drugs and are confronted with the chronic exposure to the toxic effects 
of immunosuppressive agents. Besides metabolic abnormalities such as 
diabetes mellitus, hyperlipidemia, hypertension and nephrotoxicity, even at 
the lower therapeutic doses of the calcineurin inhibitors (cyclosporine and 
tacrolimus), 80% of recipients have some degree of impaired renal function 
and 4% may develop renal failure with half of them requiring renal 
transplantation.16 In addition, the growing susceptibility to infection and the 
rising risk of malignancy add an increasing toll to the outcome. While more 
promising medications will become available, efforts have been made to 
induce recipient tolerance specific to the transplanted donor organ. Future 
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applications of the donor-specific-tolerance induction in human may 
eventually lead to complete elimination of toxic immunosuppressive drugs. 
Another major problem facing transplant clinicians is the recurrence of the 
original diseases, which may occur in the patients with autoimmune diseases 
(such as primary biliary cirrhosis, primary sclerosing cholangitis and 
autoimmune hepatitis) and viral hepatitis (such as hepatitis B and C). It has 
been found that there is a direct correlation between overall 
immunosuppression, particularly steroids and antilymphocyte preparation, 
and viral replication. Although with regular administration of anti-hepatitis B 
specific immunoglobulins, hepatitis B relapse has become rare, almost all 
patients transplanted for hepatitis C will relapse despite the use of ribavirin. 
In some of them, fluctuating transaminases, cholestasis and fibrosis will 
eventually develop and progress to liver failure.13 
The issue of utmost importance, however, is the widening gap between the 
rising number of potential recipients and the limited number of donors. Till 
1999, the number of patients waiting for liver transplantation has reached 
over 11,000 in the United Stats, and, tragically, many of them would have 
lost their lives before a proper donor is available, as figure shows that more 
than 1,000 patients on the waiting list died in 1997 alone.17 In the Euro-
Transplant countries as well as in the United Kingdom, the mortality rate of 
patients on the waiting list is about 15 to 18%.4 To address the problem of 
donor shortage, transplant surgeons are looking at new techniques to make 
better use of those organs that are offered. With marginal donor, such as 
older donors (> 60 years), history of alcoholism, elevated transaminase, 
steatosis, and prolonged reamination, the uncertainty stays at whether there 
will be early graft function after transplantation. These donors who were 
turned down in the past are now being routinely utilized with success. In rare 
situations, even a liver with a metabolic defect, such as familial amyloidotic 
polyneuropathy, has been implanted into patients who would otherwise die. 
Further efforts are required to better define the donor criteria, so that the 
usable marginal organs can be distinguished from those that are unlikely to 
function. Other targets remain to make better match of donors and recipients, 
and to have greater understanding of the mechanism of ischemia-reperfusion 
injury.11, 18, 19 The technique of splitting livers allows two patients to benefit 
from one donor, one with the right and the other with the left liver lobe. 
Besides that two transplant teams are needed to complete the recipients’ 
operations, expertise and skill to divide a liver properly are essential for 
successful use of this technique.20, 21. With the advantage of short cold 
ischemia time, the use of a living related donation is another way to expand 
the donor pool. The elective nature of this procedure allows it to be 
performed at the best time for the recipient.22-25 As the donor operation is not 
done for the physical benefit of the healthy donor and faces a complication 
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rate of 13-20% and even mortality,26 moral and ethical considerations are 
raised on this approach. These innovative techniques have predominantly 
been employed in children, and up to 40% of the paediatric patients may be 
candidates for one of these modified procedures.27, 28 The increasing shortage 
of donors has also encouraged the attempt to use animals as donors of 
transplant organs. Up to date, eight whole-organ liver transplants have been 
carried out using livers from chimpanzee, baboon and pig.29-31 Only one 
recipient was able to survive for more than 70 hours.32 Hyperacute rejection is 
the major cause of death in the immediate post-transplant period after a xeno-
transplantation.33 Using transgenic animals bearing human complement 
regulatory proteins or modulating the antigenic target on the donor organ will 
be the first step to successful xeno-transplantation.34 Further problems still 
remain to be solved on acute and chronic rejection; uncertainty of the 
physiological effects of the animal proteins produced by xenograft; and the 
risk of contamination of humans by animal viruses. Although recent clinical 
studies suggest that hepatocyte transplantation may be useful for providing 
metabolic support during liver failure to bridge patients to whole organ 
transplantation, and for replacing whole organ transplantation in metabolic 
liver diseases of certain type, shortage of human livers available for 
hepatocyte isolation and the necessitate for long-term immunosuppression are 
two major hurdles to widespread application of this procedure.35 Current 
researches in experimental models are aimed especially at developing a 
tightly regulated human hepatocyte cell line that grows economically in 
culture and exhibits differentiated liver functions.36 Similarly, a bio-artificial 
liver support system capable of sustaining the life of the patients with acute 
liver failure could lead to improved survival and an effective device may even 
be able to support the recovery of the native liver without liver 
transplantation. However, systems as such are still under investigation.37, 38 
Auxiliary Liver Transplantation: specificities and difficulties 
In comparison to orthotopic liver transplantation (OLTx), in which the 
diseased native liver is totally removed and replaced by a liver graft, 
auxiliary liver transplantation (ALTx) is characterised by leaving a whole 
or a part of the native liver in situ in parallel to an implanted hepatic graft. 
This concept is originated from an experimental work of Welch in 1955.39, 40 
Despite the fact that dramatically improved survival rate has made OLTx the 
standard treatment for the patients with end-stage liver diseases, theoretically, 
ALTx has several advantages over OLTx. Firstly, in case the graft is 
damaged by severe post-transplant rejection or vascular complications, which 
would otherwise lead to a fatal consequence of hepatic failure in OLTx, the 
remnant native liver in ALTx may provide some degree of synthetic and 
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clearing liver function. The imminent death of the recipient or the necessity 
for immediate re-transplantation may thus be obviated.28, 41-43 Secondly, liver 
grafts obtained by innovative surgical techniques such as split and living 
related donor are often relatively small in size and may not always provide 
sufficient function for OLTx. These grafts can still be useful for ALTx, where 
matching of the donor and the recipient body size is not required.44-46 Thirdly, 
an auxiliary liver may enable patients with terminal hepatic failure to be 
“bridged” for a few days or possibly weeks until a proper liver donor 
becomes available, and in this case a heterotopic procedure could preserve 
the orthotopic site for subsequent transplantation. An efficient auxiliary graft 
may even “bridge” the patient till the native liver recovers. For this purpose, 
concordant species could be potential donors of auxiliary “bridging” livers for 
selected patients when the need for transplantation is extremely urgent.34, 47, 48 
The first auxiliary liver transplantation in human was performed by Absolon 
in 1964,49 and it was till 1972 when an auxiliary transplantation truly 
prolonged a human life.50 During the following two decades, ALTx was done 
solely in a heterotopic manner - heterotopic auxiliary liver transplantation 
(HALTx), where a graft (usually partial) is placed below the un-resected 
native liver. The initial clinical results of HALTx were rather disappointing. 
Amongst the reported fifty HALTx during the period 1964-1984, only two 
patients survived longer than a year, and one of them lived fourteen and half 
years after transplantation with a well functioning graft.51-53 One of the major 
problems associated with HALTx is the limited space in the abdominal cavity 
for an additional large liver graft and the gravity gradient of the venous 
outflow caused by implanting the engrafted liver at a non-physiological 
position. This may lead to insufficient venous drainage of the engrafted liver 
and inadequate portal perfusion of the engrafted and even the native liver.54 
An insufficient reperfusion of the liver graft could cause primary non-
function immediately after transplantation, and, at the long-term, graft 
atrophy may occur due to inter-liver competition.55-59 Though the portal 
“banding” technique is a common practice to secure a sufficient amount of 
portal flow to the graft,56-59 the difficulty often remains on the proportional 
distribution of portal blood to the two livers according to the purpose of the 
transplantation.60 Vascular complications especially thrombosis of the portal 
vein are also more likely to develop after HALTx than OLTx. The high 
morbidity and mortality caused by these disadvantages have led to temporary 
abandonment of HALTx in the early 70s. Many efforts have been made ever 
since to improve post-transplant survival. Most notably, based upon the 
experiences in animal studies,53, 61-66 the contributions of Terpstra’s group 
have improved the surgical techniques of HALTx with markedly increased 
post-HALTx survival rate.54, 58, 66-71 Since 1980s’, the concept of ALTx has 
further been extended by the introduction of a new approach - auxiliary 
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partial orthotopic liver transplantation (APOLTx), where the left or the 
right lobe of the native liver is resected and replaced by an auxiliary graft.28, 
41, 42, 72-78 The physiological position of the hepatic graft by this approach 
results in an optimal outflow pressure. Accumulating clinical results have 
shown a reduced incidence of post-transplant portal thrombosis,41, 77, 79 and 
banding of the portal vein to the native liver is also less required except in 
cases of non-cirrhotic metabolic liver diseases.42, 78, 80, 81 Since the use of only 
segments 2 and 3 of the graft usually provides sufficient function, this 
technique is commonly performed with reduced-size, split or living related 
donor livers.28, 43, 81, 81 
Up to date, ALTx, particularly APOLTx, has been considered as a successful 
alternative to OLTx in specific clinical situations. HALTx, which avoids the 
surgical trauma of more extensive liver dissection, has been used to treat 
selected patients with end-stage chronic liver diseases at high risk for 
OLTx.52, 67-69, 82-84 Currently, most of the alleged difficulties of native 
hepatectomy are no longer relevant for experienced surgeons.54 The major 
concern for using HALTx to treat patients in this category lies on the original 
disease in the remaining native liver, which may further affect the engrafted 
liver, and may promote secondary tumour development. 
Children suffering from liver diseases represent about 15% to 20% of the 
liver transplant registrants.85 They have a specific spectrum of indications 
with mainly hepatic-based inborn errors of metabolism.86 Since many of 
these diseases cause structural hepatic damage and eventually lead to 
cirrhosis, whole-liver replacement by OLTx is the preferred procedure. For 
certain types of non-cirrhotic metabolic disorders, such as type 1 Crigler-
Najjar syndrome, urea cycle enzyme deficiencies, disorders of fatty acid 
metabolism, familial hypercholesterolemia, hemophilia and ornithine 
transcarbamylase deficiency, an auxiliary liver may correct the partial 
enzymatic deficiency responsible for the disease without the need to remove 
the otherwise normal native liver.41, 42, 78, 81, 86-89 ALTx also preserves the 
patient’s native liver, which remains accessible for future gene transfer 
therapy.27, 90, 91 Difficulties stay on how to determine the optimal graft volume 
required to correct the metabolic deficiency, to appreciate the necessary portal 
supply to the two livers and to avoid the possible damaging effects of the 
retaining diseased native liver. The long-term prospect of this procedure 
needs more time to adjudge. 
It has been shown that even with optimal intensive care, less than 20% of the 
patients with acute liver failure and sub-acute liver failure may survive 
without a liver transplantation.92, 93 Even though the failing liver may have the 
potential to regenerate with time, most patients will suffer fatal neurologic 
damage before the liver recovery actually occurs. To date, liver 
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transplantation is still the best life saving procedure for many patients with 
acute liver failure. Although ALTx was initially proposed as a “bridge” to 
“tide the patient over” the period of acute hepatic insufficiency,40 currently, 
most of the lives of the patients with acute liver failure are saved by OLTx 
with a one-year survival rate of over 60%.94-96 Evidently, the potential 
recovery of the failing liver is completely negated by the total removal of the 
native liver in the OLTx procedure, and the majority of the patients who 
survive the OLTx surgery have to depend on life-long use of 
immunosuppressive drugs. In contrast, an auxiliary liver graft may provide 
temporary functional support for the patient to allow the native liver to 
recover. Following a sufficient recuperation of the diseased native liver, the 
auxiliary liver graft can then be either removed or left to atrophy. The toxic 
immunosuppressive agents can be tapered or eventually withdrawn, and its 
consequent complications will thus be avoided.57-59, 72, 75-77, 97-109 Recently, 
Erhard et al. have demonstrated the feasibility of using arterialised portal 
supply to sustain the liver graft in ALTx for acute liver failure patients. The 
main advantage of this modified approach is to leave the hilum and the portal 
vein of the native liver untouched, which may reduce the incidence of 
possible complications such as arterial vascular stenosis or portal vein 
thrombosis caused by performing intrahilar vascular dissection and 
anastomosis. It also avoids disturbance of the native liver recovery due to 
“portal flow steal phenomenon”.110, 111 Current difficulties of using ALTx to 
treat patients with acute liver failure are mainly twofold: (1) There is still a 
lack of reliable pre-operative measurements to assess regenerating potential of 
the native liver for selecting appropriate candidates for the procedure. Indeed, 
histological evaluation of the presence of viable hepatocytes, fibrosis or 
regeneration in the diseased liver does not appear to have clear predictive 
value;99, 112, 113 (2) The remaining, severely diseased native liver may put the 
newly engrafted liver at risk and lead to functional failure, or may also cause 
development of the so-called “toxic liver syndrome” with subsequent multi-
organ failure.104, 114, 115 
Rat Model of Auxiliary Liver Transplantation: evolution and questions 
The first animal liver transplantation was performed in the dog by Welch in 
195539 and later studies described this attempt in other animal species 
including the baboon,116 the monkey,117 the pig,118 the mouse119 and the rat.120 
The use of genetically well-defined inbred strains of rats allows indeed a 
variety of experiments to be set up with controlled immunological features. 
This, in addition to other advantages, has made the rat the most commonly 
used experimental animal for liver transplantation studies, since large animals 
such as the pig or the dog are of limited use for immunological studies due to 
8  CHAPTER 1  General Introduction 
the difficulty of obtaining inbred strains. 
In 1966, Lee and Edgington introduced the first rat model of ALTx. In this 
initial model, 32% of the donor liver was implanted at a heterotopic position; 
the blood supply of the engrafted liver was exclusively arterial from the 
recipient’s coeliac axis; and the venous return of the graft went through the 
suprahepatic inferior donor vena cava anastomosed to the infrahepatic native 
cava. The portal vein, the infrahepatic inferior vena cava and the common 
bile duct of the liver graft were ligated. Apart from a liver mass reduction of 
approximate 68%, the portal vein and the hepatic arterial supply as well as 
the bile drainage of the recipient’s native liver remained intact.120 Further 
modification was added to this model by the same authors two years later. At 
this time, the engrafted liver was re-vascularized with both the portal venous 
and the hepatic arterial supply, while the native liver was deprived of portal 
blood. The bile drainage of the engrafted liver was not yet reconstructed. 
Serum aspartate aminotransferase activity and histology were used as 
indicators of allogeneic liver rejection. In addition to the description of histo-
pathological changes during the rejection process, it was also observed that 
re-establishing portal supply to the engrafted liver would prompt graft 
regeneration. It was therefore concluded that the portal blood flow was the 
major factor influencing liver regenerative capacity.121 
Kort et al. reported a technique, in which the infrahepatic donor vena cava 
was used to drain the engrafted liver in the rat HALTx model. It appeared 
that this modification could drastically reduce the incidence of post-transplant 
graft congestion, which was frequently seen in the original model. 
Consequently, the survival rate after HALTx was improved. However, neither 
the hepatic artery nor the bile drainage of the engrafted liver was re-
constructed.122 
Further improvement of survival was obtained by performing the procedure 
of re-connecting the graft common bile duct to the recipient’s duodenum.123 
A delicate method to share portal blood supply between the two livers was 
later described by Hess et al. The engrafted liver was perfused with 
mesentericosplenic venous blood, while the native liver retained the 
pancreaticoduodenal portal flow along with hepatic arterial supply. Due to 
technical difficulties, hepatic arterial supply to the engrafted liver was not re-
established.124 By examining the effects of different surgical manipulations of 
the native liver on the graft regeneration, their studies showed that the fate of 
the auxiliary liver graft was directly influenced by the functional state of the 
recipient’s native liver independent of the amount of portal blood flow.124, 125 
Müller reported his version of rat HALTx in 1983, in which the liver graft 
was implanted in the left loin following a left nephrectomy. The auxiliary 
liver was supplied with sole arterial blood through an anastomosis between 
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the recipient's left renal artery and the graft’s portal vein, while the hepatic 
artery of the graft was ligated. This made it the first rat model of ALTx with 
an arterialised portal supply. Venous outflow of the engrafted liver was 
drained into the recipient’s vena cava through an anastomosis between the 
inferior vena cava of the graft and the left renal vein of the recipient. The 
common bile duct of the engrafted liver was connected to the recipient’s left 
ureter. No surgical manipulation was done on the native liver. Instead of 
conventional hand-sutured technique, an intra-vascular polyethylene “stent” 
was used to connect the graft’s portal vein to the recipient’s renal artery. This 
simplified technique shortened the total ischemic time of the graft and led to 
an improved two-week survival rate of 77% after transplantation. In this 
specific setting of a portal-arterialised liver graft functioning in parallel with a 
normal native liver, the isogenic auxiliary liver graft showed gradual atrophy, 
but its histological microstructure was preserved even six months after 
transplantation.126 
The “cuff” technique, or extra-vascular stent, is another approach to simplify 
the method of micro-vascular anastomosis. It was applied in rat HALTx 
surgery by Marni et al. to perform both portal vein and vena cava 
anastomoses. With this method, occlusion time of the recipient’s portal vein 
needed to perform the portal anastomosis and the total ischemic time of the 
liver graft were considerably decreased, which contributed to a two-week 
survival rate as high as 90%. To favour the competitive position of the 
engrafted liver, the recipient’s native liver was handicapped with both a 
partial hepatectomy and a common bile duct ligation, while no re-
arterialisation of the graft was attempted. Two months after the 
transplantation, the engrafted livers enlarged to a size twofold that of the 
original ones, whereas the recipient’s native livers appeared atrophic. The 
authors mentioned the interest of using this model for transplantation 
immunology studies.127 
Lee et al. described two specific variations of rat HALTx in 1986. The first 
one was called the “double-liver” model, in which the suprahepatic inferior 
vena cava of the engrafted liver was anastomosed to the infrahepatic portion 
of the recipient inferior vena cava; the graft’s portal vein was anastomosed 
more distally to the recipient’s inferior vena cava at the level of the renal 
vein. The inferior vena cava between the two anastomoses was then ligated, 
which led to the perfusion of the engrafted liver with systemic venous blood. 
The graft’s hepatic artery was anastomosed to the recipient’s infrarenal aorta. 
No manipulation was done on the native liver. Along with its later arterial-
venous fistula version,128-130 this model was designed to study liver 
regeneration following transplantation. The second variation introduced by 
Lee was the so-called “reversed circulation” model. The recipient’s portal 
vein was connected to the suprahepatic vena cava of the engrafted liver, and 
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the engrafted liver was drained through an anastomosis between the graft’s 
portal vein and the recipient’s infrahepatic vena cava. The native liver was 
thus deprived of its portal supply. This model was developed to study the 
effects of a reversed circulation on the hepatic physiology.131 
Schleimer et al. recently reported a new approach in the rat HALTx, in which 
the portal vein of the engrafted liver was arterialised via the recipient’s renal 
artery.132 The difference with Müller’s technique is that the engrafted liver’s 
outflow was made possible through an anastomosis performed directly 
between the donor and the recipient vena cava, and the bile duct was re-
connected to the recipient’s duodenum. The recipient’s native liver was 
subjected to an 85% partial hepatectomy in order to induce acute liver failure. 
With the support of a portal arterialised auxiliary liver, the failing native liver 
regenerated to about 2.5% of the body weight and 83% of the rats did survive 
an observation period of three months.133 
To date, two different types of APOLTx models have been described in the 
rat. The partial liver graft was implanted at an orthotopic site either above - in 
a reversal fashion134, 135 or at the left side of the partial hepatectomised native 
liver.136 
The rat model of ALTx has been used for various studies such as to evaluate 
new surgical techniques,120, 122, 123, 126, 127, 131, 135, 137, 138 and related 
physiological128, 128, 139, 140 or morphological changes of the liver;141, 142 to test 
its feasibility for correcting metabolic deficiency143-146 or for maintaining 
hepatic function and supporting native liver regeneration at the time of acute 
liver failure;133 to study transplantation immunology126, 147-149, 149-152 and to 
investigate the mechanisms of inter-liver functional competition.120, 121, 124, 125, 
133, 153-160 
In addition to technical difficulties, there are other problems with the use of 
the rat model of HALTx. Comparing to OLTx, the rat model of HALTx is 
characterized by the coexistence of the engrafted liver and the recipient’s 
native liver after the transplantation. The commonly used parameters such as 
animal survival and serum biochemical tests could thus not discriminate the 
functionality of each individual liver. The question remains on how to 
evaluate the post-transplant viability of an individual liver, especially the 
engrafted organ. A possible approach is to handicap the native liver to such a 
degree that it will be insufficient to guarantee survival. The post-transplant 
animal survival and liver biology will then necessarily reflect the viability of 
the newly engrafted liver. In the previous studies, different surgical 
manipulations of the native liver have been used for this purpose either with a 
68% partial hepatectomy alone 121, 122 or with a 68% partial hepatectomy plus 
a common bile duct ligation.123, 127 Up to date, there has been no report on the 
possible differential effects of these various approaches on post-transplant 
CHAPTER 1  General  Introduction  11 
animal and graft survival, as well as the animal serum biochemical values. 
This was investigated in the current work. Furthermore, as a non-invasive 
measurement, magnetic resonance imaging (MRI) was tested for its capability 
to monitor the post-transplant hepatic viability in this rat model. 
After HALTx, the interaction of the two livers also influences transplantation 
immunology126, 147-149, 149-152 and may play a role in the inter-liver competition. 
Starzl et al. were among the first to observe that an auxiliary liver graft would 
atrophy in the presence of a healthy recipient’s native liver after HALTx.161, 
162 The term of “functional competition”, which was originally used to 
describe the compensatory hyperplasia of one liver lobe after occlusion of the 
bile duct of the other lobe,163 was applied to depict this phenomenon. This 
competitive behaviour of the two livers has also been noticed later in the 
APOLTx.42, 78, 80 Despite many efforts made over the past three decades, the 
precise mechanisms of this phenomenon are still not fully understood. Some 
investigators claim that atrophy or hypertrophy of the liver graft is the result 
of the functional competition between the two livers governed by the body 
demand for liver function. Shalm164 and Hess et al.123 showed that atrophy of 
the auxiliary liver together with functional deterioration of the graft was due 
to the presence of the recipient’s un-handicapped native liver. Van der Heyde 
et al. demonstrated in the dog that by increasing a certain degree of functional 
impairment on the native liver, for instance through performing a common 
bile duct ligation, the graft atrophy could be prevented.165 Hess confirmed 
these results in a rat model and showed that the auxiliary engrafted liver 
would be replaced by connective tissue if no manipulations on the native liver 
were done.123 Van der Heyde et al. also reported that a host portacaval shunt 
would enhance the function of the graft and prevent its atrophy.166 In 
contrary, other investigators dispute this theory and emphasize the importance 
of portal blood itself for maintenance of hepatic graft integrity by showing 
that the graft atrophy can be prevented by diversion of all portal flow through 
the graft.162, 167 Using a “split transposition” dog model, Marchioro et al. 
reported that the liver fragments receiving splanchnic blood were always 
hypertrophic compared with the hepatic lobes perfused by systemic venous 
blood. Their studies suggested that only the splanchnic portal inflow, which 
carried certain substances, was essential for the preservation of hepatocytes 
integrity and could boost liver regeneration.162, 168, 169 In a series of studies 
using this “double fragment model”, in which the separated two liver 
fragments were provided with blood of various sources, Starzl et al. claimed 
that the main splanchnic venous “hepatotrophic factors” were endogenous 
hormones, amongst which the single most important was insulin.170-173 While 
new substances with hepatotrophic effect continue to emerge, to date, it has 
generally been accepted that hormone hepatotrophic factors are the key 
elements for liver regeneration. Therefore, after HALTx, the liver that 
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receives the major part of portal supply will eventually regenerate, and the 
final outcome of the inter-liver competition actually depends upon the 
distribution of the “hepatotrophic factors” between the two livers.42, 56-59, 80, 153, 
154, 162, 170, 171, 174-178 No consensus exists so far on whether the physiological 
status of each individual liver may influence the inter-liver competition. This 
was investigated in the current work using a rat model of HALTx, in which 
the physiological balance was favourably slanted towards either the engrafted 
liver or the recipient’s native liver through surgical manipulations. In 
addition, an effort was also made to re-examine the controversy on whether 
changing the content of the portal supply would alter hepatic regeneration 
capacity following a standard partial hepatectomy. 
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SUMMARY 
In the rat model of heterotopic auxiliary liver transplantation, the coexistence 
of the engrafted liver and the recipient’s native liver makes it difficult to 
evaluate the post-transplant graft viability. In this study, auxiliary liver 
transplantation was performed in Wistar rats, in which the recipient’s native 
liver was handicapped with a 68% partial hepatectomy and a common bile 
duct ligation. Serum biochemistry of the liver was analysed and compared 
with that of the selected control group. The surgical handicap of the liver 
showed severe damaging effects: the handicapped native livers appeared 
atrophic at autopsy and no long-term animal survival could be achieved 
without an auxiliary liver transplantation. As the engrafted liver corrected 
the cholestasis of the handicapped native liver, significant differences of 
serum biochemistry were found between the transplanted group and the 
control group: for bilirubin concentration and gamma glutamyl transferase 
activity from post-operative day 3 to 28 (p < 0.05); alkaline phosphatase on 
day 3, 7, 14 and 28 (p < 0.05); alanine aminotransferase activity on day 3 
and 14 (p < 0.05) and aspartate aminotransferase activity on day 14 (p < 
0.05). The efficiency to induce hepatic failure and to hamper its regeneration 
capacity in the native liver makes animal survival and liver biology as 
reliable parameters to evaluate the post-transplant graft viability in this rat 
model. 
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INTRODUCTION 
Although the first attempt of liver transplantation in human was a 
heterotopic auxiliary liver transplantation (HALTx) (1), orthotopic liver 
transplantation (OLTx) has long been accepted as the standard treatment for 
end-stage liver diseases. This is mainly due to the poor results of clinical 
HALTx. However, HALTx has always been theoretically attractive with 
advantages over OLTx in some specific cases (2-4). HALTx avoids the 
surgical trauma of more extensive liver dissection and the an-hepatic phase 
needed for the transplantation. For the patients with end-stage chronic liver 
disease at high risk for OLTx, HALTx certainly represents a life-saving 
alternative (5). In addition, a heterotopic auxiliary liver may correct some 
inborn errors of metabolism with enzymatic deficiency without removing the 
otherwise normal liver (6). Above all, HALTx is particularly useful for 
treating patients with fulminant and subfulminant hepatic failure in whom 
the function of the native liver may still recover. Following a successful 
recuperation of the native liver, the auxiliary liver can then be removed, thus 
avoiding the life-long use of immunosuppressive drugs and its potential 
complications. This has been proven by encouraging clinical results from 
different organ-transplantation centres in recent years (7-10). 
However, the engrafted liver and the recipient’s native liver may behave 
competitively to each other. As a consequence, the atrophy of the engrafted 
liver is the major cause of the failure in HALTx. Even though this “inter-
liver competition” phenomenon was recognized as early as at the beginning 
of clinical and experimental HALTx (11, 12), its mechanisms still remain 
incompletely understood. Amongst other experimental protocols, the rat 
HALTx is an ideal model to perform studies related to this more exceptional 
but important clinical situation (13, 14). 
As the engrafted liver coexists with the recipient’s native liver in this rat 
model, how to evaluate the post-transplant graft viability was an open 
question. In the current study, the function of the native liver was surgically 
handicapped. The most commonly used serum biochemical parameters were 
tested as possible indicators to evaluate the post-transplant evolution of the 
engrafted liver. 
MATERIALS AND METHODS 
Experimental Animals 
All animals of this study received care in accordance with institutional, 
national and European guidelines. Male out bred Wistar rats (B & K 
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Universal Limited, England) weighing 240-320g were used. The rats had 
free access to food and water before surgery. 
Experimental Groups (Table 1) 
HALTx group (n = 12): HALTx was performed in all rats of this group, in 
which the recipient’s native liver was handicapped with both a 68% partial 
hepatectomy (68% PH) and a common bile duct ligation (CBDL). 
In order to evaluate post-transplant liver biology, a proper control group with 
long-term animal survival was selected from four experimental models: 
Group 1  (n = 10). The liver handicapped in the same way as for the 
recipient’s native liver in the HALTx group: a portacaval 
shunt (PCS), a 68% PH and a CBDL. 
Group 2  (n = 10). A PCS and a 68% PH. 
Group 3  (n = 10). A PCS and a CBDL. 
Group 4  (n = 10). A 68% PH and a CBDL. 
Surgical Techniques 
All operative procedures were carried out under ether anaesthesia with clean 
but non-sterile instruments, and x 12.5 magnification. During the operation, 
the body temperature of the rat was maintained at approximately 36°C by 
using heating pads. 
(a)  HALTx: The HALTx was performed according to the technique 
described elsewhere (15). Briefly, 32% of the donor liver was 
used for transplantation after perfusion with cold (4° C) 
heparinized physiological saline solution via the portal vein. The 
native liver of the recipient rat was handicapped with both a 68% 
PH and a CBDL, while the hepatic artery remained intact. 
Following a right nephrectomy, the engrafted liver was implanted 
in the right paravertebral gutter under the native liver of the 
recipient. The cuff technique was used for the anastomoses of 
both the vena cava and the portal vein. The engrafted liver 
received its blood supply from the portal vein of the recipient. 
The venous drainage was made through the right renal vein of the 
recipient to the vena cava. Restoration of the bile drainage was 
done by insertion of the intubated common bile duct of the donor 
liver into the recipient duodenum. No re-arterialisation of the 
engrafted liver was attempted in this study. The graft fixation was 
performed to avoid twisting and kinking of the donor vena cava 
as previously reported (15) (See photo illustration at the end of 
this section). 
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During the operation, cold ischemia time of the engrafted livers 
(starting from saline perfusion via the portal vein and ending at 
portal re-vascularization of the engrafted liver) was kept between 
72 and 79 minutes. 
(b)  PCS: The method described by Lee (16) was modified with the 
cuff technique to perform a PCS. After a left nephrectomy, the left 
renal vein was freed up to the vena cava, which was then cross-
clamped. An incision was made into the anterior wall of the stump 
of the left renal vein. The portal vein was divided from the pyloric 
vein to the liver hilus, tied, transsected and cuffed with a 0.4 cm 
length polyethylene tube. The cuffed portal vein was then inserted 
into the left renal vein and secured with a 5-0 ligature. 
(c)  68%PH: The median lobe and the left lobe of the liver were 
ligated and then excised according to the standard method 
introduced by Higgins and Anderson (17). 
(d)  CBDL: The common bile duct was double ligated with non-
absorbable sutures and the segment in between was then removed. 
Post-operative Care and Follow-up 
All rats were given intra-muscular injection of 10 mg Na Cefazolin 
immediately after surgery and this was repeated daily for three days. No 
immunosuppressive agent was administered to the rats. During the following 
twenty-four hours, rats were given 5% glucose to drink, after which the pre-
operative diet of food pellets and water was resumed. 
All rats were observed daily and survival time of each rat was recorded. 
For the serum biochemical analysis, a blood sample of 0.4 - 0.5 ml was 
collected from the rat's tail vein pre-operatively, on the post-operative day 3, 
7, 14, 21, 28, 56 and 84. Serum bilirubin concentration (TBil), gamma 
glutamyl transferase activity (GGT), alkaline phosphatase (ALP), alanine 
aminotransferase activity (ALAT), aspartate aminotransferase activity 
(ASAT), lactate dehydrogenase (LDH) and total protein (TP) were 
determined by using BM / Hitachi System 747 (Boehringer Mannheim 
GmbH, Diagnostica). The reference intervals (range) used in this laboratory 
were for serum TBil 0.00 – 0.20 ml/dl, GGT 0 U/l, ALP 58.18 – 328.14 U/l, 
ALAT 17.38 – 59.55 U/l and ASAT 51.73 – 107.89 U/l. 
An autopsy was performed whenever a rat died. The long-term survivors 
were sacrificed at the end of the 3-month observation period. The livers were 
excised, cleaned of gross adhesions, and fixed in 10% formalin. Four-micron 
thick sections were stained with hematoxylin and eosin (HE) or trichrome 
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Table 1. Experimental groups and post-operative animal survival 
Experimental groups Survival time (days, mean ± SD) 
Control groups 
 G1 (n = 10): PCS + 68% PH + 
CBDL 
 G2 (n = 10): PCS + 68% PH 
 
0.5 ± 0.3 
0.8 ± 0.6 
 Survival rates 
 1 week 1 month 2 months  3 months 
Control groups 
 G3 (n = 10): PCS + CBDL 
 G4 (n = 10): 68% PH + CBDL 
HALTx group (n = 12) 
 
100% 80%  20%  20% 
100%  100%  80%  50% 
100% 66%  50%  50% 
Note: PCS, portacaval shunt; 68% PH, 68% partial hepatectomy; CBDL, common 
bile duct ligation; HALTx, heterotopic auxiliary liver transplantation. 
Statistical Analysis 
The data were expressed as the mean ± standard deviation (SD). The 
distribution of the data was checked by Kolmogorov test. The Student's t-test 
was applied for the normally distributed data, while the not-normally-
distributed data were evaluated by the Mann-Whitney rank sum test. P 
values equal to or less than 0.05 were considered statistically significant. 
RESULTS 
Post-operative Animal Survival (Table 1) 
HALTx group. All 12 rats survived the first post-transplant week. The 1-
month and the 3-month survival rate were 66% and 50%, respectively. The 
causes of post-operative deaths were mainly due to liver abscess (3/6), 
cholangitis (1/6), peritonitis (1/6) and rejection (1/6). The biochemical data 
of the six long-term survival rats were compared with that of the control 
group. 
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Control groups. Despite the comparable vascular cross-clamping time, all 
rats in the group 1 died of liver failure within 24 hours after surgery and in 
the group 2 reduced liver handicap could not significantly improve animal 
survival. In the group 3, two out of ten rats died of infectious complications 
(cholangitis and peritonitis) during the 1st post-operative month and six rats 
that died between the 1st and the 2nd month showed signs of biliary 
congestion with ascites. The 2-month survival rate was only 20% in this 
group. All 10 rats of the group 4 survived the first post-operative month. One 
rat died of pneumonia later on and cholangitis caused the other 4 animal 
losses. The 3-month survival rate of this group was 50%. 
Serum Biochemical Analysis 
Since none of the rats in the group 1 and 2 survived longer than two days and 
the 2-month survival rate of the group 3 was as low as 20%, only the data of 
the group 4 were available to compare with those of the HALTx group. 
The most commonly used serum biochemical parameters (TBil, GGT, ALP, 
ALAT, ASAT, LDH and TP) were evaluated as possible indicators of liver 
viability for this rat model. No significant differences between the two 
groups were found for LDH and TP. 
Serum TBil, GGT, ALP, ALAT and ASAT levels were elevated in the rats of 
two groups after surgery. However, the rats in the HALTx group had 
significantly lower values of TBil than that in the group 4 on day 3 (p < 
0.001), 7 (p < 0.001), 14 (p < 0.001), 21 (p < 0.001) and 28 (p < 0.005) 
(Figure 1a). The same profile appeared for GGT on day 3 (p < 0.001), 7 (p < 
0.01), 14 (p < 0.05), 21 (p < 0.005) and 28 (p < 0.05) (Figure 1b). Serum 
ALP also showed a pronounced difference between the two groups on day 3 
(p < 0.01), 7 (p < 0.05), 14 (p < 0.05) and 28 (p < 0.01) (Figure 1c). In the 
HALTx group, serum ALAT was significantly lower than those of the group 
4 on day 3 (p < 0.05) and 14 (p < 0.001) (Figure 1d) while ASAT differed 
significantly between the two groups on day 14 (p < 0.05) (Figure 1e). 
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Figure 1. Comparison of serum biochemical tests (mean ± SD) between the 
HALTx group () and the control group 4 (): (a) bilirubin concentration 
(TBil), (b) gamma-glutamyl transferase activity (GGT), (c) alkaline 
phosphatase (ALP), (d) alanine aminotransferase activity (ALAT) and (e) 
aspartate aminotransferase activity (ASAT). Asterisk indicates statistically 
significant differences between the two groups. * p  0.05, ** p < 0.01 and *** 








































Figure 2. Histological findings of 3-month survival rats: (a) HALTx group: 
The engrafted liver preserved its normal lobular architecture without major 
histopathological alterations (original magnification x 125). (b) Control group 
4: The liver completely lost its general lobular architecture with the 
proliferation of the cholangioles lined by swollen cuboidal epithelium (original 
magnification x 125) 
.
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Autopsy and Histology 
Three months after the transplantation, the 6 long-term survivors of the 
HALTx group were sacrificed for histological analysis. At autopsy, the 
engrafted livers of these rats appeared normal in size and colour and the 
cuffed portal vein and vena cava anastomoses remained patent. These 
engrafted livers revealed a normal lobular architecture without major 
histopathological alterations (Figure 2a), whereas the general lobular 
architecture of the handicapped native livers was lost and replaced by 
ductular metaplasia in the portal tracts accompanied by fibrosis. 
In the group 4, the 5 long-term survival rats were also sacrificed 3 months 
after the surgery. A bile duct cyst of 1-3 cm diameter was found in the 
hepatic hilus of all animals. The livers were macronodular with 
disappearance of the general lobular architecture characterised by the 
proliferation of the cholangioles lined by swollen cuboidal epithelium 
(Figure 2b). There was no substantial difference with the native liver of the 
recipient in HALTx group. 
DISCUSSION 
Since the technique of HALTx in rat was first described in 1966 (13), this rat 
model has been used in experimental researches of various subjects such as 
liver regeneration, hepatotrophic factors, allogenic microchimerism and graft 
rejection (18-20). As the two-liver state in this model makes it difficult to 
evaluate the viability of the engrafted liver after the transplantation, a 
possible approach is to handicap the recipient’s native liver to such a degree 
that it will eventually cease its function. In this study, liver failure was 
induced surgically by means of handicapping the native liver with both a 
68% PH and a CBDL. Corresponding to a previous observation (14), it 
appeared that this handicap could damage the organ so severely that not only 
the liver failure was assured causing animal death, but also the hepatic 
regeneration capacity was completely impaired leading to atrophy in long-
term survivors. Therefore, the post-transplant animal survival relays 
primarily upon the function of the engrafted liver, and the serum 
biochemistry of the liver reflects the viability of that engrafted organ despite 
the presence of the recipient’s native liver. 
In evaluating the post-transplant graft viability, the combination of a PCS, a 
68% PH and a CBDL should be the most appropriate control since the native 
liver in the HALTx group was handicapped in the same way. However, 
without an auxiliary liver, this approach was always lethal. A reduced 
handicap with a PCS and a 68% PH also failed to significantly improve 
a 
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animal survival. Although the rats subjected to a PCS plus a CBDL did 
survive longer, a 2-month survival rate of 20% could not provide sufficient 
data for a long-term comparative study. Most rats of this group died between 
the 1st and 2nd post-operative month with signs of cholestasis and ascites, 
which indicated that this handicap could induce a subacute liver failure. In 
the absence of long-term survival, no real control or comparison could be 
done and even less traumatic surgical procedures had to be tested. A 68% PH 
plus a CBDL without a PCS eventually appeared to be the only viable 
control of this model, which facilitated a long-term comparison of serum 
biochemistry with the HALTx group. 
Along with autopsy and pathological examination, post-operative animal 
survival is indeed a commonly used parameter to evaluate the viability of the 
engrafted liver after HALTx. However, survival rate does not allow to 
evaluate, for instance, the degree of the liver injury caused by preservation 
and re-perfusion, and to appreciate the post-operative complications of the 
engrafted liver. Serum biochemistry of the liver is an un-invasive 
measurement, which can be used for systematic evaluation of graft viability 
by simple means. In contrary to previous publications (18, 21), in this study, 
LDH was not significantly different between the HALTx group and the 
control group. This could be due to the fact that LDH is an enzyme present 
in a wide variety of tissues including heart, skeletal muscle, kidney and brain 
in addition to the liver. Thus muscle trauma induced by the operative 
procedures can interfere and influence LDH value mainly in the early 
observation phase. Since TP measures different sorts of proteins, which may 
be affected positively or negatively by the experimental interventions, it 
lacks specificity for the liver function as shown in this study. 
Serum TBil, GGT and ALP are the parameters directly linked to 
hepatobilirary cholestasis. In the present study, the serum levels of TBil, 
GGT and ALP increased drastically in the rats of the control group after a 
68% PH and a CBDL, but not in the HALTx group despite the fact that the 
recipient’s native liver was subjected to the same handicap. This 
demonstrated that the function of bile secretion was mainly taken over by the 
engrafted liver from the recipient’s native liver, which was consequently less 
cholestatic. During the first post-operative month, the significantly lower 
levels of serum TBil, GGT and ALP in the transplanted rats were thus a sign 
of proper function of the engrafted liver. The elevation of serum ALAT and 
ASAT immediate after the operation indicated hepatocellular damage in both 
the transplanted and the control groups. The lower peak values and faster 
normalisation of both parameters in the rats of the HALTx group suggested 
that the engrafted liver reduced the deleterious effect of cholestasis on the 
native liver. 
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As the high success rates of the HALTx procedure can be achieved with a 
sole portal blood supply, the re-arterialisation of the engrafted liver has not 
been considered as a necessity for this rat model (14, 22, 23). However, 
using OLTx model, the recent studies have demonstrated the beneficial 
effects of the re-arterialisation on improving micro-vascular perfusion (24), 
modifying the expression of class I and II MHC antigens (25, 26), 
maintaining an adequate oxygen supply and tissue ATP (27), reducing the 
post-transplant biliary complications (28-30) and increasing animal survival 
rate (31, 32). Whether equal mechanisms may be implicated in the HALTx 
has not yet been addressed. As the interaction between the engrafted and the 
native liver added an important element to this specific rat model, this 
question indeed warrants further attention. 
In conclusion, the data of present study show that in this rat model of 
HALTx, handicap of the native liver with a 68% PH and a CBDL can 
efficiently induce liver failure and hamper its regeneration capacity. The 
post-transplant animal survival and normalization of the liver biology reflect 
well the viability of the engrafted liver. 
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Donor liver preparation 
After a 68% partial hepatectomy, 
the common bile duct was 
intubated; the portal vein and the 
vena cava were isolated. 
 
Donor liver perfusion 
The donor liver was then perfused 
with cold saline solution through 
the portal vein. 
 
Cuff preparation 
Both the portal vein and the vena 
cave of the graft were cuffed with 
a polyethylene tube. 
 
Recipient preparation 
The native liver of the recipient 
was handicapped with a 68% PH 
and CBDL. The portal vein and 
the right renal vein were prepared 
for vascular anastomoses. 
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Graft venous outflow 
The venous drainage of the 
engrafted liver was made through 
the right renal vein of the recipient 
to the vena cava. 
Graft blood supply 
The engrafted liver received its 
blood supply from the portal vein 
of the recipient. 
Graft bile drainage 
The intubated common bile duct 
of the graft was inserted into the 
recipient duodenum. 
Graft fixation 
The remained donor diaphragm 
was fixed to the recipient’s lateral 
abdominal wall. 
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the Native Liver in a Rat Model of Heterotopic Auxiliary Liver 
Transplantation: a pilot study 
Ye-Dong Fan1, Bart Vanzieleghem2, Eric Achten2, Yves De Deene2, Luc Defreyne2, 
Marleen Praet3, Jacques Van Huysse3, Marc Kunnen2 and Bernard de Hemptinne1 
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SUMMARY 
Following a heterotopic auxiliary liver transplantation, commonly used 
measurements are either invasive or non-indicative of individual viability of 
the coexisting engrafted and native livers. Magnetic resonance imaging 
(MRI) was therefore tested for its potential to monitor the post-transplant 
hepatic viability in a rat model. Thirteen Wistar rats were systematically 
evaluated with MRI and serum biochemical liver parameters. Post-transplant 
complications and the causes of animal death were identified by autopsy and 
histo-pathological examinations. The data of the healthy survivors were 
compared with those of the rats that developed complications. On MRI, the 
hepatic complications could be depicted in the individual livers. A specific 
pattern of signal evolution was found in the livers of the healthy survivors: 
the mean T1 relaxation times of the engrafted livers increased immediately 
after transplantation (476 ± 64 ms, mean ± standard deviation, pre-operative; 
730 ± 48 ms, week 1) and then declined steadily to a three month value of 
489 ± 246 ms; while, following a transient first rise (476 ± 64 ms, pre-
operative; 589 ± 28 ms, week 1), the mean T1 value of the native livers 
increased again four weeks after surgery and reached a three month value of 
859 ± 43 ms. However, in the rats with various complications, the mean T1 
relaxation times of the engrafted livers continued to increase throughout the 
first post-operative month (760 ± 48 ms, week 1; 922 ± 76 ms, week 4), 
while that of the native liver only varied mildly (546 ± 25 ms, week 1; 473 ± 
25 ms, week 4). After the first post-transplant week, the healthy engrafted 
livers could already be distinguished from those with complications by a 
significant decrease in T1 relaxation times. These data suggest that, besides 
demonstrating major complications, MRI may allow one to monitor the 
viability of each liver by analysing the relative signal intensity and T1 
relaxation times after a heterotopic auxiliary liver transplantation. 
NMR in Biomedicine 2001; 14:350-359 




In heterotopic auxiliary liver transplantation (HALTx), a donor liver graft is 
implanted into the recipient without complete removal of the diseased native 
liver. This operative procedure avoids the surgical trauma of more extensive 
liver dissection and the an-hepatic phase needed in case of orthotopic liver 
transplantation (OLTx). For the patients with end-stage chronic liver disease 
at high risk for OLTx, HALTx can indeed be a life saving alternative 1. In 
addition, without removing the otherwise normal liver, an auxiliary liver 
may correct some inborn errors of metabolism with enzymatic deficiency 2,3. 
Above all, HALTx has the advantage over OLTx in treating patients with 
fulminant and sub-fulminant hepatic failure in whom the function of the 
native liver may still recover. Following a successful recuperation of the 
native liver, the auxiliary liver can then be removed or left to atrophy, thus 
avoiding the life-long use of immunosuppressive drugs and its potential 
complications 4-9. 
Despite these advantages, HALTx has not widely been used. Comparing to 
OLTx, HALTx is technically more demanding with a higher incidence of 
post-transplant complications such as arterial and venous thrombosis. 
Moreover, as the remaining native liver is functionally competing with the 
newly engrafted liver, graft atrophy is another major cause of failure 10,11. 
Since the so-called “hepatotrophic factors” are generally accepted as the 
prime factor for the preservation of hepatic integrity, a proper sharing of the 
portal blood between the two livers is important for the success of the 
procedure 12. Up to date, a reliable method of dividing the portal blood flow 
proportionally between the two livers is still lacking. Careful monitoring of 
the post-transplant evolution of the two livers is therefore crucial, since an 
early identification of complications can lead to a possible surgical 
correction or other interventions that may reverse the otherwise failing 
procedure. In case of a HALTx for fulminant or sub-fulminant hepatic 
failure, an accurate assessment of the regeneration of the native liver is also 
important to define the exact time to taper and eventually to stop 
immunosuppression, and possibly to remove the engrafted liver 13. Amongst 
the most commonly used measurements for the post-transplant evaluation, 
biological tests of the liver can only show the global hepatic function rather 
than the respective contributions of each individual liver. Although the 
individual function of the engrafted liver or the native liver is assessable by 
Hida scintigraphy 14,15, various post-transplant complications that may lead 
to graft dysfunction, such as acute rejection, vascular occlusions, biliary 
obstruction and abscess formation, cannot be distinguished by this technique 
16; besides, the procedure uses radioactive tracers. Histological examination, 
which does show the state of the examined organ accurately, requires 
invasive biopsy procedures and cannot be repeated frequently without risk. 
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As a non-invasive technique, magnetic resonance imaging (MRI) may have 
the advantages of providing reliable information of each individual liver 
after a HALTx. Moreover, the post-transplant evolution of the two livers 
recorded by a systematic MRI monitoring may be useful for studies on the 
mechanisms of “inter-liver competition” with important impact on liver 
transplantation and hepatological research. This potential had not yet been 
explored so far and was tested in the current study using a rat model of 
HALTx. 
MATERIALS AND METHODS 
Experimental Animals 
Male outbred Wistar rats (B & K Universal Limited, England) weighing 
280-350 g were used as donors and recipients. All the animals received 
humane care according to the European guidelines for animal care (Het 
Belgisch Staatsblad, Feb. 29th, 1992). The rats had free access to water and 
standard pellet food. Before surgery, food but not water was withdrawn from 
the recipient rats for 12 hours. 
Experimental Design 
The combination of a 68% partial hepatectomy (68% PH) and a common 
bile duct ligation (CBDL) does severely handicap the function of the native 
liver and cause atrophy. An engrafted liver in this condition can benefit from 
stimulating trophic factors circulating in the portal system to regenerate 17. 
This operative procedure with drastic changes in the engrafted and the native 
liver was specifically chosen to test the potential of MRI in post-transplant 
monitoring. 
MRI measurement and serum biochemical liver tests were carried out on a 
regular basis. An autopsy and subsequent histo-pathological examination 
were performed whenever a rat died or at the end of the 3-month follow-up 
period when all the long-term survivors were sacrificed. 
Sixteen rats were subjected to HALTx. Only the rats that survived the 
surgical procedure longer than one week were used for systematic post-
transplant evaluation, while those that died within the first post-operative 
week were regarded as surgical failure and excluded from the study. Based 
upon autopsy and histo-pathological evidence, the rats were subdivided into 
two groups: group 1 consisted of the rats free of any complications; the rats 
that developed post-transplant complications including infection, biliary 
obstruction, vascular thrombosis and rejection were included in group 2. The 
data of MRI, liver biology and histology of these two groups were 
compared. 




All operations were performed with ether anaesthesia, clean instruments and 
x 12.5 microscopic magnification. Body temperature of the rats was 
maintained at approximately 36°C by using heating pads during surgery. 
HALTx was performed according to the technique described elsewhere 18. 
Briefly, after a 68% PH, the donor liver was perfused with cold (± 4° C) 
heparinized Ringer’s solution via the portal vein. Following a right 
nephrectomy, the liver graft was implanted in the right paravertebral gutter 
under the native liver of the recipient. The cuff technique was used for the 
anastomoses of both the vena cava and the portal vein. The engrafted liver 
received its portal blood supply from the portal vein of the recipient. The 
venous drainage was made by connecting the infrahepatic vena cava of the 
donor liver to the right renal vein of the recipient. No re-arterialisation of the 
engrafted liver was attempted in this study. Restoration of the bile drainage 
was done by insertion of the intubated common bile duct of the donor liver 
into the recipient’s duodenum. As the portal flow of the recipient was 
completely shunted to the engrafted liver, the blood supply of the native liver 
remained solely from the hepatic artery. The native liver was further 
handicapped with both a 68% PH and a CBDL. 
For all the operative procedure of HALTx in the rats of both groups, the cold 
ischemia time of the liver grafts was kept between 62 and 74 minutes. The 
duration of warm ischemia of the liver grafts (from the implantation to the 
blood re-circulation of the engrafted liver) was between 11 and 14 minutes. 
At the end of the operation, the rats were transfused with 1-1.5 cc of 
Ringer’s solution and an intramuscular injection of 10 mg Na Cefazolin was 
given. No immunosuppressive agent was administered. The pre-operative 
diet of food pellets was resumed 2 hours after the operation. 
MR Evaluation 
During MRI examination, the rat was anaesthetised with 1.2 vol % 
isoflurane through a gas mask. Examinations were performed on a 1.0 Tesla 
scanner (EXPERT, SiemensTM Germany) using a standard circular polarised 
knee-coil with a diameter of 25 cm. Each MR experiment lasted less than 30 
minutes. To establish the reference value of T1 relaxation time in the normal 
rat liver, thirteen rats of the same strain free of any surgical manipulation 
were scanned. MRI examinations of the transplanted rats were performed 
pre-operatively and weekly during the evaluation period of three months. An 
extra five rats subjected only to a 68% PH and a CBDL without HALTx 
were also evaluated weekly during the first post-operative month to identify 
the effects of these surgical interventions on the status of the native liver. 
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For visual evaluation, the rats were scanned with 4 mm thick axial slices 
with T1-weighted contrast (T1W) (TR/TE/NEX = 400 ms/12 ms/4), and 2 
mm thick coronal slices with T1W contrast (400 ms/12 ms/4). 
For quantitative evaluation, proton relaxometry with calculation of T1 
relaxation times in the engrafted and the native livers was carried out. For 
this, a spin-echo sequence was used and measurements were repeated with 
different repetition times (TR/TE = 2000,1000,500,250/12 ms). A T1 
relaxation curve was obtained by plotting the signal intensities in a region of 
interest in the engrafted and the native livers as a function of the repetition 
time. The T1 relaxation time was extracted from the plots by fitting the data 
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with S0 and T1 as the unknown variables. Fitting was performed by use 
of a home-written computer program based on the Levenberg-Marquardt 
algorithm, as this is proven to be preferable above other fitting methods with 
regard to signal-to-noise consideration 19. 
Liver Biology 
A blood sample of 0.4 - 0.5 ml was collected from the rat's tail vein for 
serum biochemical tests. Using routine photometric tests on a Hitachi 747 
analyser, serum alanine aminotransferase activity (ALAT) and bilirubin 
concentration (TBil) were determined pre-operatively and further on the 
post-operative day 3, 7, 14, 21, 28, 56 and 84. 
Autopsy and Histology 
During each autopsy, the examination was focused on the macroscopic 
appearance of the engrafted and the native liver, the patency of the vascular 
anastomoses and the common bile duct, the complications and the possible 
causes of animal death where premature death occurred. 
The livers were excised, cleaned of gross adhesions, and fixed in a 10% 
formalin solution. Four-micron-thick sections were stained with hematoxylin 
and eosin (HE), and examined light-microscopically. 
Statistics 
The data were expressed as the mean ± standard deviation (SD). The 
distribution of the data was checked by Kolmogorov test. The Student's t-test 
or the Mann-Whitney rank sum test was applied for normally or not-
normally distributed data, respectively. P values equal to or less than 0.05 
were considered statistically significant. 




Post-operative Animal Survival 
Three out of the sixteen rats were excluded from the study due to early post-
operative death. One rat died of bleeding on the second day, while peritonitis 
secondary to bile leakage caused another two animal losses on the third and 
fourth day. Amongst the thirteen rats that survived longer than one week 
after HALTx, four appeared normal during the observation period of three-
month and no signs of infection, biliary obstruction, vascular thrombosis and 
rejection were found at sacrifice. These four rats were included in group 1. 
Among the nine rats of group 2, eight developed various complications and 
died during the first seven weeks after transplantation (1 in week 2, 2 in 
week 3, 1 in week 4, 1 in week 5, 1 in week 6 and 2 in week 7). Cholangitis 
(n = 4), liver abscess (n = 2), vena cava thrombosis (n = 1) and rejection (n = 
1) were found to be the major causes of animal death. Only one out of nine 
rats in group 2 survived longer than seven weeks, which was sacrificed at the 
end of the eighth week due to abnormal MRI data. Portal vein thrombosis of 
the engrafted liver was identified. 
MRI 
Using anatomical landmarks, the engrafted and the native liver could clearly 
be distinguished from each other on MR images. In the rats without 
complications (group 1), both livers remained homogeneous throughout the 
observation period. Notably, the signal intensity of the two livers showed a 
transition on the T1W images during the observation period: the signal 
intensity of the engrafted livers evolved from hypo-intense to hyper-intense, 
while that of the native livers changed from hyper-intense to hypo-intense 
(Figure 1a). In comparison, in the rats with post-transplant complications 
(group 2), the signal of the engrafted livers was in-homogeneous and showed 
low signal areas on T1W images at various times. These hypo-intense areas 
were later identified as complications such as abscess formation. Moreover, 
no transition of signal intensity was observed: the signal intensity of the 
engrafted liver remained hypo-intense, while that of the native liver was 
constantly hyper-intense even in the rat that was sacrificed two months after 
HALTx (Figure 2a). 
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Figure 1. (a1-4) Post-HALTx evolution of signal intensity of a rat in group 1 
(in a series of 2, 4, 6 and 12 weeks). Relative to that of the other liver, the 
signal intensity of the engrafted liver (T) evolved from hypo-intense to hyper-
intense, while that of the native liver (N) changed in opposite direction during 
the 3 months observation period. ‘’ shows the interface between the two 
livers. BC indicates a bile cyst. (b) Autopsy observation (3 months post-
HALTx). The engrafted liver revealed a normal appearance with patent portal 
vein and vena cava anastomoses (indicated by ‘’); (c) Histological findings 
(3 months post-HALTx). The engrafted liver (T) preserved its normal lobular 
architecture without major histo-pathological alterations, while that of the 
native liver (N) was completely destroyed and replaced by ductular 
metaplasia in the portal tracts accompanied by fibrosis (original 
magnification x 125, HE staining). 
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Figure 2. (a1-3) Post-HALTx evolution of signal intensity of a rat in group 2 
(in a series of 1, 2 and 4 weeks). Relative to that of the other liver, the signal 
intensity of the engrafted liver (T) remained hypo-intense, while that of the 
native liver (N) became more hyper-intense. The hypo-intensity in the 
engrafted liver (A) was identified as an abscess at autopsy. ‘’ shows the 
interface between the two livers. BC indicates a bile cyst. (b) Autopsy 
observation (7 weeks post-HALTx). The engrafted liver (T) appeared 
atrophic and an abscess (A) was observed, while the size of the native liver 
(N) was less changed. (c) Histological findings (7 weeks post-HALTx). 
Besides remnants of hepatocytes, the general lobular architecture was 
hardly visible in the engrafted liver (T), which contained an abscess (A) (HE, 
original magnification x 100). The native liver (N) revealed ischemic necrosis 
of the hepatocytes (HE, original magnification x 250). 
The evolution of the signal intensity was the visual reflection of changing T1 
relaxation times (Figure 3). The reference T1 value of the liver established 
from thirteen normal rats was 476 ± 64 ms. In group 1, the mean value of the 
T1 relaxation time of the engrafted livers showed a transient increase 
immediately after HALTx with a peak value in the first post-operative week 
(476 ± 64 ms, pre-operative; 730 ± 48 ms, week 1). Thereafter, the value fell 
back to the pre-transplant level at the one-month time point (464 ± 26 ms) 
and remained around this same range till the end of observation period of 
three months (489 ± 24 ms). Parallel to the evolution of the engrafted livers, 
the mean T1 value of the native livers increased only slightly from a pre-
operative value of 476 ± 64 ms to 589 ± 28 ms in the first week. The value 
increased again one month after the transplantation, kept on rising to another  
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Figure 3. Post-HALTx evolution of mean T1 relaxation time (ms) in group 1 
(  , the engrafted livers;   , the native livers) and in group 2 ( --
- , the engrafted livers;  --- , the native livers; , the engrafted liver 
and , the native liver of the rat that was sacrificed at the end of the second 
post-transplant month). Values are expressed as mean ± SD. The asterisk 
indicates statistically significant differences between the engrafted livers of 
group 1 (  ) and the engrafted livers of group 2 ( --- ). ** p < 0.01; 
*** p < 0.001. 
peak in the seventh week (737 ± 33 ms), and remained high till the end of 
the third month (859 ± 43 ms). 
In contrast to the pattern presented by group 1, group 2 showed a rather 
different profile (Figure 3). Instead of an initial increase followed by a 
decrease, the mean T1 relaxation time of the engrafted livers in this group 
continued to increase throughout the first post-operative month (476 ± 64 
ms, pre-operative; 922 ± 76 ms, week 4), while that of the native livers only 
varied mildly during the same period of time (476 ± 64 ms, pre-operative; 
473 ± 25 ms, week 4). This high T1 in the engrafted liver and low T1 in the 
native liver was again recorded in the rat that was sacrificed at the end of the 
second post-transplant month (959 ms, the engrafted liver; 415 ms, the 
native liver). Compared with the engrafted livers in group 1, the mean T1 
relaxation times of the engrafted livers in group 2 were significantly higher 
in the second (p = 0.005), the third (p = 0.001) and the fourth post-transplant 
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Table 1. Comparison of post-operative T1 relaxation time (ms) between the 
native livers of experimental groups and the livers subjected only to 
68% PH and CBDL 
 68% PH/CBDL NL-Group 1 NL-Group 2 
 (n = 5) (n = 4)  
 Pre-operative reference value: 476 ± 64 
 week   1 519 ± 54 589 ± 28 546 ± 25 (n = 9) 
 week   2 537 ± 81 485 ± 25 483 ± 24 (n = 8) 
 week   3 446 ± 52 427 ± 23 447 ± 18 (n = 6) 
 week   4 602 ± 50       340 ± 13***     473 ± 25 (n = 5)*** 
 week   8  673 ± 21  
 week 12  859 ± 43  
Notes: 68% PH: 68% partial hepatectomy; CBDL: common bile duct ligation; NL: 
native liver. Data are expressed as mean ± SD. The asterisk indicates statistically 
significant differences between the values of experimental group and that of the rats 
subjected only to 68% PH and CBDL. *** p < 0.001. 
During the first three post-operative weeks, as shown in Table 1, the mean T1 
relaxation time of the native livers in both group 1 and 2 was similar to that 
of the livers subjected only to 68% PH and CBDL, all of which remained in 
or slightly above the normal range (476 ± 64 ms). This might indicate that 
the significantly higher T1 value of the livers subjected only to 68% PH and 
CBDL in the fourth week (p < 0.001) as well as the constantly elevated T1 of 
the native livers in the rats of group 1 four weeks after HALTx were caused 
by the factors beyond surgical trauma. 
Liver Biology 
The mean serum ALAT values elevated in both group 1 and group 2 after 
transplantation, reached peak levels on the third day and then returned to 
normal range in two-weeks time. The mean ALAT values of group 2 showed 
a more marked increase than that of group 1 on day 3 (199 ± 57 U/l vs. 91 ± 
54 U/l; p = 0.05) (Figure 4a). Serum TBil revealed pronounced differences 
between the two groups as shown in Figure 4b. Compared with those of 
group 1, the mean TBil values of group 2 were significantly higher on the 
seventh (1.31 ± 1.49 mg/dl, group 1; 12.52 ± 4.94 mg/dl, group 2; 
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Figure 4. Post-HALTx evolution of (a) mean serum alanine 
aminotransferase activity (ALAT, U/l) and (b) mean bilirubin concentration 
(TBil, mg/dl) in group 1 () and group 2 (). Values are expressed as mean 
± SD. The asterisk indicates statistically significant differences between the 
two groups. * p ≤ 0.05; ** p < 0.01; *** p < 0.001. 
p < 0.001), the fourteenth (0.48 ± 0.34 mg/dl, 13.26 ± 2.81 mg/dl, 
respectively; p < 0.001), the twenty-first (0.63 ± 0.54 mg/dl, 8.26 ± 2.79 
mg/dl, respectively; p = 0.005) and the twenty-eighth day (0.53 ± 0.34 
mg/dl, 6.63 ± 2.01 mg/dl, respectively; p = 0.007). 
Autopsy and Histology 
At sacrifice, the four long-term survivors of group 1 showed enlarged liver 
grafts with normal appearance and patent anastomoses of the portal vein and 
the vena cava (Figure 1b), while their native livers were atrophic. The 
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engrafted livers was well preserved, while that of the handicapped native 
livers was completely altered and replaced by ductular metaplasia in the 
portal tracts accompanied by fibrosis (Figure 1c). 
In contrast, all the engrafted livers of the rats in group 2 appeared atrophic, 
while the size of the native livers was less changed (Figure 2b). As a result 
of common bile duct ligation, a bile cyst was observed at the hilus of the 
native livers in all the rats of group 1 and 2. Histological examination 
showed a drastically destructed lobular architecture of the engrafted livers 
due to cholangitis, rejection, portal vein thrombosis and liver abscess, while 
various degree of ischemic hepatocytes necrosis was observed in the native 
livers (Figure 2c). 
DISCUSSION 
MRI seems an excellent technique to monitor changes in both the engrafted 
and the native liver after a HALTx. As the anatomical border of each liver is 
identifiable, the post-transplant complications, such as intra- or inter-hepatic 
abscess and liver necrosis, can visually be depicted. Moreover, the data of 
this study show that, in the absence of steatosis 20, the better the hepatic 
viability, the higher the signal intensity on T1W images. This finding 
corresponds well with a previous report by Siegelman and his colleagues, in 
which the similar signal pattern has been observed in a clinical case 21. The 
signal intensity of the liver on each MR image indicates therefore the 
viability of the organ at that specific time point, especially in respect to its 
physiological position in the inter-liver competition, even when no obvious 
complications can yet be seen. MRI could thus have great clinical 
applications as an indirect and accurate measurement of hepatic viability. A 
technique as such is particularly needed in some clinical situations, for 
instance pre-surgical evaluation of transplant candidate in fulminant or sub-
fulminant hepatic failure, post-transplant or post-hepatectomy assessment of 
liver viability. 
Several experimental and clinical studies have demonstrated a close 
correlation between T1 relaxation time and the water content of the liver 
tissue: the lower the T1 value, the lower the water content 22-26. In addition, a 
low T1 may also be indicative of a normal bile production and energy 
metabolism 22. As normal water content can only be preserved with integrity 
of cell membranes, an elevated T1 could reflect the processes such as edema, 
cell death, disintegration and inflammation in the examined organ 23. The 
transient post-transplant increase of T1 value in the engrafted and the native 
livers observed in this study may reveal the degree of hepatic trauma caused 
by surgery. Following a peak value, the constantly decreasing T1 relaxation 
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times of the healthy hepatic grafts demonstrate the recuperating process of 
the engrafted livers from the preservation and re-perfusion injury. 
Meanwhile, the functional deterioration of the handicapped native livers 
caused by biliary obstruction and partial hepatectomy is represented by the 
elevation of the T1 relaxation time one month after HALTx. When the 
engrafted livers fully recover and eventually take over the hepatic function, 
the native livers enter a phase of progressive atrophy. MRI records this 
“take-over” as a cross-point around the fifth post-transplant week. As a 
functioning engrafted liver may reduce the toxic effects of the cholestasis of 
the handicapped native live, the discrepancy of the T1 values between the 
native livers of the transplanted group and the handicapped livers without 
HALTx may be interpreted as another sign of this recovery. On the other 
hand, if a complication such as biliary obstruction, vascular thrombosis and 
abscess formation occur in the engrafted livers, this normal pattern is no 
longer seen. With increasing inflammation, the T1 relaxation times of the 
engrafted livers, instead of declining, keep on rising after transplantation. 
Meanwhile, less altered T1 relaxation times recorded in the native livers 
reveal that the handicapped organs remain relatively normal to compensate 
the functional deterioration of the engrafted livers. 
In addition, as early as after the first post-transplant week, a dramatic 
difference of the T1 relaxation times of the engrafted livers could be found 
between the healthy long-term survivors and the rats with complications. 
This observation may indicate that if no MRI sign of recovery from the 
operative trauma appears at this time, the engrafted liver is developing either 
an acute or a chronic complication. The eventual outcome of the engrafted 
liver and the native liver in the inter-liver competition can therefore be 
predicted at an early post-transplant stage through MRI analysis. 
A previous study has shown that, in this specific rat model of HALTx, the 
functionality of the native liver is so severely damaged by surgical handicap 
that the rat will die unless a viable auxiliary liver is present. In case a post-
operative complication occurs in the engrafted liver at a later stage, the 
animal is unable to survive, as the handicapped native liver is already 
atrophic at that time 17. Despite a portal vein thrombosis developed in the 
engrafted liver, however, a rat of group 2 in this study survived longer than 
two months following transplantation. The T1 relaxation time of its native 
liver prior to sacrifice was in the normal range. The reason why this 
handicapped native liver is still able to maintain certain function for such a 
long period is unknown. The progressive nature of portal vein thrombosis 
after transplantation may explain part of this observation. 
Although definitive conclusions can only be drawn from a larger sample 
study, the data of this pilot experiment do show the beneficial potential of 
using MRI in post-HALTx monitoring. Prospective clinical investigations 
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are indeed worthy to test the findings of this study that major post-transplant 
complications can be depicted individually by this measurement, and that the 
hepatic function is also assessable by analysis of the signal intensity and T1 
relaxation times. These studies will demonstrate if the final outcome of each 
liver may be forecasted as early as after the first post-transplant week. As 
MRI allows documenting the evolution of the engrafted and the native liver 
systematically and non-invasively, this procedure can thus facilitate the 
studies on inter-liver functional competition. 
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CHAPTER 3 
STUDY OF INTER-LIVER FUNCTIONAL COMPETITION 
FOLLOWING HETEROTOPIC AUXILIARY LIVER 
TRANSPLANTATION 
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3.1. The Need to Handicap the Recipient's Native Liver in the Rat 
Model    of Heterotopic Auxiliary Liver Transplantation 
Ye-Dong Fan1, Marleen Praet2 and Bernard de Hemptinne1 
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Ghent, Belgium. 
SUMMARY 
In the rat model of heterotopic auxiliary liver transplantation (HALTx), the 
opinion varies on whether and how the recipient’s native liver should be 
handicapped. To avoid atrophy of the transplanted organ, in this study, two 
different handicaps were evaluated and their effects on post-operative animal 
survival and liver biology were described. With a sole portacaval shunt 
(group 1) all rats survived longer than 3 months. An additional handicap of 
the liver with either a 68% partial hepatectomy (68% PH) (group 2), or both 
a 68% PH and a common bile duct ligation (CBDL) (group 3) led to a 100% 
lethality within 2 days after surgery. When an auxiliary liver was 
transplanted to the rats handicapped with a 68% PH (group 4), serum TBil 
and ALAT values were significantly lower than those handicapped with both 
a 68% PH and a CBDL (group 5). Autopsy and histology of the long-term 
survivors revealed the atrophy of the engrafted livers and the regeneration of 
the native livers in group 4 whereas it showed the opposite in group 5. Thus 
the various manipulations of the native liver do influence differently the 
post-transplant animal survival, serum liver biochemistry and the outcome of 
the engrafted liver in this rat model of HALTx. 
HPB Surgery 1999; 11:225-234 
CHAPTER 3  Study of Inter-liver Functional Competition  63   
 
INTRODUCTION 
In recent years, more and more reports from different organ-transplantation 
centres have been published about encouraging results of using heterotopic 
auxiliary liver transplantation (HALTx) to treat patients with end-stage liver 
diseases especially fulminant and subfulminant hepatic failure 1-3. This has 
raised new attention to study the potential problems of this operative 
procedure with animal models 4-5. HALTx in the rat has long been used for 
experimental research, since it was first described by Lee and Edgington in 
1966 6. The investigators have used this model to study amongst others, liver 
regeneration, hepatotrophic factors, allogeneic microchimerism and graft 
rejection 5,7,8. Several technique modifications of this model have been 
introduced in that respect 9-12. 
Although the observation of graft atrophy and the concept of “inter-liver 
competition” in HALTx were reported in the early 60's 13-15, opinion still 
varies on whether in this rat model the native liver of the recipient should be 
handicapped and in this case which approach should be used. Some authors 
handicapped the native liver either with a 68% partial hepatectomy (68% 
PH) 7, 10 or a 68% PH plus a common bile duct ligation (CBDL) 9, 11. Others, 
on the contrary, left the native liver intact 5, 8, 12. Up to date, there has been 
no report about how these different manipulations of the native liver do 
influence the post-HALTx animal survival and serum biochemical values. 
This was investigated in the present study. 
MATERIALS AND METHODS 
Experimental Design (Table 1) 
To evaluate the effects of different handicaps on the native liver, three 
experimental groups were studied, in which the livers were put in 
functionally similar situations as the native livers in the HALTx model: 
group 1 (n = 10), an end-to-side portacaval shunt (PCS) (without further 
handicap of the liver); group 2 (n = 10), a PCS plus a 68% PH as additional 
handicap of the liver; and group 3 (n = 10), a PCS, a 68% PH and a CBDL to 
handicap the liver. 
Two experimental groups were tested later on, since no long-term survivor 
and thus serum biochemical evolution could be obtained from the rats of 
group 2 and 3. In group 4 (n = 12), a HALTx was performed after the native 
liver was handicapped in the same way as in group 2 (PCS and 68% PH). In 
group 5 (n = 12), HALTx was performed after the handicap of the native 
liver as in group 3 (PCS, 68% PH and CBDL). 
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Experimental Animals 
Male Wistar rats weighing 250-340g were purchased from Janssen 
Pharmaceutica N.V., Belgium. Donor and recipient rats were matched for 
size. Rats had free access to food and water prior to surgery. All animals 
received humane care as outlined in the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 86-23, revised 1985). 
Surgical Techniques 
All operations were carried out under ether anaesthesia with clean but non-
sterile instruments and x 12.5 magnification. 
(a)  68% PH: The median lobe and the left lobe of the liver were 
ligated and then excised according to the standard method 
introduced by Higgins and Anderson 16. 
(b)  CBDL: A segment of the common bile duct was removed after 
double ligation. 
(c)  PCS: The standard method described by Lee 17 was modified using 
the cuff technique to perform a PCS. After a left nephrectomy, the 
left renal vein was freed up to the vena cava, which was then cross-
clamped. An incision was made into the anterior wall of the stump 
of the left renal vein. The portal vein was divided from the pyloric 
vein to the liver hilus, tied, transsected and cuffed with a 0.4 cm 
length polyethylene tube. The cuffed portal vein was then inserted 
into the left renal vein and secured with a 5-0 ligature. 
(d)  HALTx: The standard technique described by Marni 9 was used 
with a slight modification. After the donor liver was perfused 
with heparinized 4°C physiological saline solution via the portal 
vein, 32% of the liver was used for transplantation. The native 
liver of the recipient rat was handicapped with a 68% PH or both 
a 68% PH and a CBDL according to the study group, while the 
hepatic artery remained intact. The engrafted liver was then 
implanted in the right paravertebral gutter under the native liver 
of the recipient. The cuff technique described by Kamada 18 was 
used for the anastomoses of both the vena cava and the portal 
vein. The engrafted liver received its blood supply from the portal 
vein of the recipient. The venous drainage was made through the 
right renal vein of the recipient to the vena cava. Restoration of 
the bile drainage was done by insertion of the intubated common 
bile duct of the donor liver into the recipient duodenum. No re-
arterialisation was performed. To this standard procedure, we 
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added a fixation of the remaining donor diaphragm to the 
recipient lateral abdominal wall in order to avoid twisting and 
kinking of the donor vena cava. 
The duration of the different operative phases (mainly the portal vein and the 
vena cava cross-clamping time) was comparable among group 1, 2 and 3. 
The cold preservation time of the grafts (starting from the saline perfusion 
via the portal vein ending at the portal re-vascularization of the engrafted 
liver) was kept between 72 and 79 minutes in the rats of HALTx group 4 and 
5. 
Post-operative Care 
All rats were given 10 mg Na Cefazolin intramuscularly after the operation 
and this was repeated daily for three days. No immunosuppressive agent was 
administered to the rats. During the following twenty-four hours, rats were 
allowed to drink 5% glucose, after which the pre-operative diet of food 
pellets and water was resumed. 
Follow-up 
Body weight was recorded daily and survival time was determined. 
For the biochemical analysis, a blood sample of 0.4 - 0.5 ml was collected 
from the tail vein. Serum total bilirubin concentration (TBil) and alanine 
aminotransferase activity (ALAT) were determined pre-operatively, on post-
operative day 3, weekly for one month and monthly for 3 months. 
An autopsy was performed whenever a rat died to identify possible 
complications. The livers were removed at sacrifice and fixed with 10% 
formalin. Four-micron sections were stained with hematoxylin and eosin 
(HE) or trichrome. Liver samples were studied by light microscopy. 
Statistical Analysis 
The data were expressed as the mean ± standard deviation (SD). The 
Student's t-test was applied for the data analysis. P values equal to or less 
than 0.05 were considered statistically significant. 
RESULTS 
Body Weight and Animal Survival 
The body weight of all rats declined 24 hours after the operation with 
average 10.00  6.47 grams per rat in group 4 and 18.33  14.03 grams in 
group 5 (NS). Three weeks later, the rats of group 4 regained their pre-
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operative weight and even exceeded up to average 24.07  3.40 grams 
compared with 1.67  11.16 grams in group 5 (NS). 
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Table 1. Experimental groups and post-operative survival 
Experimental groups Survival time 
G1 (n = 10): PCS 
G2 (n = 10): PCS + 68% PH 
G3 (n = 10): PCS + 68% PH 
 + CBDL 
> 3 months (10/10) 
0.81 ± 0.56 days (mean ± SD) 
0.51 ± 0.30 days (mean ± SD) 
 Survival rates 
 1 week  2 weeks  3 weeks   1 month  2 
months 
G4 (n = 12): HALTx + 68% 
PH 
G5 (n = 12): HALTx + 68% 
PH  + CBDL 
100%  100%   92%  92%   83% 
100% 83%   58%  50%   50% 
Notes: PCS, portacaval shunt; 68% PH, 68% partial hepatectomy; CBDL, common 
bile duct ligation; HALTx, heterotopic auxiliary liver transplantation. 
As shown in the Table 1, the rats of group 1 could well tolerate a PCS 
whereas all rats in group 2 and 3 died of liver failure within two days after 
the surgery. 
In group 4, the 1-month survival rate was as high as 92%. Only two rats died 
of abscess in the native liver or in both the native and the engrafted livers on 
the 17th and 34th post-operative day. In group 5, only 50% of the animal 
survived longer than 3 months. Except a rat that died of rejection on day 23, 
all others died of infectious complications (cholestasis in 1, abscess in 3 and 
peritonitis in 1). 
Serum Biochemical Parameters 
Serum TBil of the rats in group 5 was significantly higher than those of 
group 4 on post-operative day 7 (p = 0.025) and 28 (p = 0.02) (Figure 1a). 
The rats (2#, 3#, 8# and 10#) of group 5, that had the highest values of TBil on 
day 7, developed infectious complications and died within the following 
weeks. By disregarding the values of those rats that died of complications, 
the differences between the two groups were still recorded but they were no 
longer statistically significant (Figure 1b). The high TBil peak of group 5 on 
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day 28 was this time due to the two rats that developed secondary biliary 
cirrhosis of the engrafted livers found later at autopsy. 
CHAPTER 3  Study of Inter-liver Functional Competition  69   
 
Figure 1. Comparison of the mean serum total bilirubin concentration (TBil) 
between group 4 and 5 post-HALTx: (a) Data of the whole group. Statistically 
significant differences were found on day 7 and day 28 (p < 0.05); (b) Data of 
the long-term survivors. No significant differences between the two groups 
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Figure 2. Comparison of the mean serum alanine aminotransferase (ALAT) 
between group 4 and 5 post-HALTx: (a) Data of the whole group. The 
statistically significant differences were found on day 3 (p < 0.05), day 21 (p < 
0.05) and day 28 (p < 0.001); (b) Data of the long-term survivors. The 
differences between the two groups were not significant on day 3 and 
remained significant on day 21 (p < 0.01) and 28 (p < 0.001). 
As showed in Figure 2a, significant differences of mean serum ALAT 
between the two groups were found on day 3 (p = 0.014), 21 (p = 0.014) and 
28 (p < 0.001). Similarly to serum TBil, the highest ALAT values of group 5 
on day 3 were again due to the rats that later died of infectious 
complications. When those values were excluded, the differences were no 
longer significant on day 3 but remained significant on day 21 (p = 0.008) 
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Figure 3: Autopsy. (a) a rat of group 4 (HALTx with a 68% PH to handicap 
the native liver) sacrificed 7 months after the operation: the engrafted liver 
() atrophied whereas the native liver had normal appearance; (b) a rat of 
group 5 (HALTx with a 68% PH and a CBDL to handicap the native liver) 
sacrificed 12 months after the operation: the size of the engrafted liver () 
enlarged and the native liver underwent complete atrophy. 
Autopsy and Histology 
After the end of three months observation period, the long-term survival rats 
were killed at different time intervals. It was found that all the engrafted 
livers of the 10 survivors in group 4 underwent atrophy at sacrifice while 
their native livers showed normal appearance (Figure 3a). The general 
architecture of those engrafted livers was altered by fibrosis and ductular 
metaplasia. Only a few groups of hepatocytes were present (Figure 4a). 
On the contrary, in group 5, the engrafted livers of all but 2 long term 
survivors appeared normal macroscopically whereas their native livers 
showed clear atrophy (Figure 3b). The general architecture of those 
engrafted livers was well preserved without major histological alterations 
(Figure 4b). The 2 remaining rats (1# and 6#) presented cirrhotic appearance 
of their engrafted livers and the histology revealed secondary biliary 
cirrhosis due to sub-obstruction of their hepaticoduodenostomy. 
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Figure 4: Histological observations. (a) a rat of group 4 (HALTx with a 68% 
PH to handicap the native liver) sacrificed 7 months after the operation: the 
general architecture of the engrafted liver was altered by fibrosis (*) and 
ductular metaplasia (**). Only a few groups of hepatocytes were present () 
(Trichrome, x 10); (b) a rat of group 5 (HALTx with a 68% PH and a CBDL to 
handicap the native liver) sacrificed 12 months after the operation: the 
general architecture of the engrafted liver was well preserved and no major 
alterations were present (HE, x 10). 
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DISCUSSION 
In the previous studies of rat HALTx, the post-operative animal survival and 
serum biochemistry were most commonly analysed without taking into 
account the role of the handicap of the native liver. In this study, we show 
for the first time how these handicaps can differently influence the post-
transplant biochemical parameters. 
The classical rat model of HALTx includes a complete shunting of the portal 
blood away from the native liver to re-vascularize the engrafted liver. In this 
case, the blood supply of the native liver is solely given by the hepatic artery, 
which corresponds effectively to a PCS of the liver. It appears that the blood 
flow of the hepatic artery can compensate the by-passed portal blood after a 
PCS and maintain a “functioning liver”, so that the effects of PCS do not 
significantly influence the animal survival. Without handicap of the native 
liver, the engrafted liver is therefore transplanted parallel with a normal 
functioning liver. The increased hepatic blood flow will not be sufficient to 
support proper hepatic function if a further handicap is carried out in the 
native liver. It is reported that in the case of a 68% PH added to an end-to-
side PCS, the rat survival does not exceed 2 days 11. The results of the 
present study confirm this data and show, as would have been anticipated, 
that the combination of a PCS, a 68% PH and a CBDL does even shorten 
this survival time. In both these circumstances, no animal can be kept alive 
unless an auxiliary liver graft is transplanted. 
The long-term survivors in the HALTx groups make it possible to perform a 
comparative study of the serum biochemistry between the rats bearing 
different liver handicaps. When the rats were handicapped only with a 68% 
PH as in group 4, ALAT increased to a peak level 1 week post-transplant but 
then returned to normal values after 2 weeks reflecting transitory 
hepatocellular damage. Both ischemic injury of the graft caused by 
preservation and the surgical manipulations of the liver at the time of 68% 
PH are responsible for this initial elevation. On the other hand, TBil of this 
group only rose slightly after the surgery even in the rats that presented fatal 
complications. This demonstrates that in case of a sole 68% PH to handicap 
the native liver, either one of the two livers can still compensate for the 
functional deficiency of the other. An additional CBDL to the native liver 
will handicap this organ so profoundly that it can no longer compensate 
when the engrafted liver is affected by an acute infectious complication: 
TBil sharply increased in these cases followed by the animal deaths shortly 
later as shown in group 5. The “double handicap” of the native liver is also 
responsible for a second peak of TBil around 1 month after HALTx. The rats 
that developed secondary biliary cirrhosis of the graft presented the highest 
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values at this time point, when the exhaustion of the regeneration potential 
and thereby the functional failure of the native liver occurred 19. The 
repermeabilisation of the extrahepatic biliary duct of the native liver may 
presumably explain the normalisation of serum TBil in the long-term 
survivors. 
It has been found that long-standing bile duct obstruction of the native liver 
impairs the function of reticuloendothelial system, which might lead to 
serious post-operative complications 20, 21. The rats handicapped with CBDL 
(group 5) had indeed a higher incidence of infection and more pronounced 
post-operative weight-loss. Cholestasis induced by CBDL also inhibits the 
metabolic functions of liver cells including mitochondrial function. As 
consequence, regeneration capacity of this organ is compromised 22, 23. These 
may be the reasons why a CBDL together with a 68% PH can affect the 
native liver to such a degree that the post-HALTx animal survival and 
normal serum biochemical values depend totally upon the functionality of 
the engrafted liver. 
HALTx has advantages over OLTx in treating acute liver failure, inborn 
errors of metabolism and, exceptionally, chronic liver diseases with high 
operative risk for OLTx. In the case of acute liver failure, the diseased native 
liver is expected to recover while the engrafted liver is providing functional 
support. The engrafted liver will then be removed or left in place to atrophy 
if the native liver resumes its proper function 1-3. For patients with chronic 
liver diseases, regeneration of the engrafted liver and atrophy of the native 
liver is the rule after a HALTx 24. Although up to now no clinical experience 
with HALTx to treat patients with inborn errors of metabolism has been 
reported, the long-term functionality of both the engrafted and the native 
livers should be looked for 4. In view of these different situations, it is indeed 
important to have a better understanding about the mechanisms of inter-liver 
competition and the right approaches to control or to modify this process. It 
is for this purpose, the rat HALTx can be an interesting model to study the 
insight of this phenomenon, even though it does not replicate the exact 
clinical situation. It is generally accepted that proper regeneration of the liver 
can only be achieved when the portal vein is re-vascularized with venous 
blood or through arterialisation of the portal stump 6, 15, 25. Interestingly, the 
partially resected native liver can still regain progressively its volume and 
function despite the lack of portal blood flow, whereas the engrafted liver 
eventually atrophies. In case of an additional handicap of the native liver, by 
means of a CBDL, the functional recuperation of the native liver is 
completely impaired while the engrafted liver takes over the function and 
keeps its normal macroscopic and microscopic aspects. These results suggest 
that besides the known hepatotrophic factors 8, 26, the diseased state of the 
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native liver also influences the outcome of the inter-liver competition. Yu 
and co-workers have shown that the atrophy of the engrafted liver can be 
prevented by its re-arterialisation even when the native liver is not 
handicapped 5. Re-arterialisation of the graft in the OLTx model reduces 
biliary complications, modifies the immunological response and improves 
micro-vascular perfusion of the graft 27-29. In the rat model of HALTx, these 
beneficial effects certainly favour the competitive position of the engrafted 
liver. 
The data of the present study show that in the rat model of HALTx the 
different manipulations on the native liver do influence not only the post-
transplant animal survival but also the serum biochemical values of the liver. 
Furthermore, handicap of the native liver limited to a 68% PH will lead to 
the atrophy of the engrafted liver, whereas a 68% PH combined with a 
CBDL is a handicap that impairs the regeneration of the native liver. In the 
latter case, the post-HALTx survival and normalisation of the serum 
biochemistry depend solely upon the viability of the engrafted liver. 
Although this model has no direct similarity with clinical condition, it allows 
further approach and understanding to the concept of inter-liver competition. 
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SUMMARY 
In the rat model of heterotopic auxiliary liver transplantation, graft re-
arterialisation may influence the outcome of inter-liver competition. This 
was investigated in the current study using two transplanted groups with or 
without graft re-arterialisation. Immediately after re-perfusion, the re-
arterialised grafts showed significantly higher bile flow rate and bilirubin 
excretion than the grafts without re-arterialisation. DNA synthesis rate was 
also increased more drastically in the re-arterialised group following the 
transplantation. Without re-arterialisation, the rats developed more 
pronounced cytolysis and cholestasis. Among the long-term survivors, all 
healthy re-arterialised grafts regenerated, whereas 5/6 non re-arterialised 
grafts atrophied. These data demonstrate that the re-arterialisation does 
increase graft survival by improving early hepatic function, enhancing 
regenerative response and preventing post-transplant biliary complications in 
this rat model. 
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INTRODUCTION 
In the rat model of heterotopic auxiliary liver transplantation (HALTx), the 
coexistence of the graft and the recipient’s native liver can induce functional 
inhibition and lead to atrophy of the newly engrafted liver [1]. Besides the 
role of hepatotrophic factors in maintaining hepatocyte integrity [2], other 
mechanisms may as well have an influence on the inter-liver competition. In 
a previous study, we showed that a certain degree of handicap on the native 
liver was needed to weaken the functional position of the native liver and to 
prevent atrophy of the graft [3]. It was evidenced that if the native liver was 
kept intact, the engrafted liver did eventually atrophy and was replaced by 
connective tissue [4]. By adding a hepatic re-arterialisation to the graft, 
atrophy could be avoided and regeneration of the engrafted liver was 
achieved [5]. 
The studies of orthotopic liver transplantation have demonstrated the 
beneficial effects of the graft re-arterialisation on improving micro-vascular 
perfusion [6], decreasing the expression of class I and II MHC antigens [7], 
maintaining an adequate oxygen supply and tissue ATP [8], reducing the 
post-transplant biliary complications [9, 10] and increasing animal survival 
rate [11]. Whether equal mechanisms might be implicated in HALTx 
remained to be analysed, as the interaction between the graft and the native 
liver added an important element to this specific rat model. 
The current study was conducted to investigate the possible impact of the re-
arterialisation on immediate graft function, regenerative response of the 
engrafted liver and post-operative graft survival and long-term outcome of 
the recipient animal in the rat model of HALTx. 
MATERIALS AND METHODS 
Animals and Experimental Groups 
Male inbred Lewis rats (Harlan Netherlands B. V., Zeist, the Netherlands) 
weighing 240-300 g were used in this study. The rats had free access to 
water and standard pellet food. Housing, humidity and day-night circle were 
strict according to European guidelines for animal care. Before surgery, food 
but not water was withdrawn from the recipient rats for 12 hours. Donors 
and recipients were matched for size. 
Two experimental groups were studied: HALTx-A group, HALTx with re-
arterialisation of the engrafted liver (n = 58); HALTx-nonA group, HALTx 
without re-arterialisation of the engrafted liver (n = 58). 
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Figure 1. Technique of heterotopic auxiliary liver transplantation with graft re-
arterialisation. The portal vein of the donor liver (DPV) was anatomised with 
the portal vein of the recipient (RPV). Using “sleeve” technique, the hepatic 
artery of the donor liver (DHA) was re-connected to the recipient’s aorta (A) 
through the right renal artery. The venous drainage of the donor liver was 
made between the donor vena cava (DVC) and the recipient vena cava 
(RVC) via the right renal vein. The recipient native liver received sole hepatic 
artery supply (RHA). 
80  3.2. Graft Re-arterialisation in Rat HALTx 
Surgical Procedure 
All operations were carried out with ether anaesthesia, clean but non-sterile 
instruments and x 12.5 magnification. Body temperature of the rats was 
maintained at approximately 36°C by using heating pads. 
Using 32% of the donor liver, HALTx was performed according to the 
technique as previously described [12]. The donor liver was perfused with 
cold (± 4° C) heparinized Ringer’s solution: 5 ml via the portal vein and 3 
ml via the hepatico-aortic segment. Following a right nephrectomy, the liver 
graft was implanted in the right paravertebral gutter under the native liver of 
the recipient. The cuff technique was used for the anastomoses of both the 
vena cava and the portal vein. The engrafted liver received its portal blood 
from the portal vein of the recipient. The venous drainage was made through 
the right renal vein of the recipient to the vena cava. In the HALTx-A group, 
the hepatic artery of the engrafted liver was re-connected to the recipient’s 
right renal artery with a 10-0 monofilament nylon suture (Tyco Health Care, 
Belgium) using the “sleeve” technique [13]. The engrafted liver was then re-
perfused simultaneously by portal and arterial blood [14]. As the total 
amount of portal flow went to the engrafted liver, the vascularization of the 
native liver was limited to sole hepatic artery supply (Figure 1). Restoration 
of the bile drainage was done by insertion of the intubated common bile duct 
of the donor liver into the recipient’s duodenum. 
The duration (mean ± SD) of cold ischemia of the liver grafts was 56 ± 7 
minutes in the HALTx-A group and 55 ± 8 minutes in the HALTx-nonA 
group. The duration of warm ischemia of the liver grafts (starting from 
implantation and ending at blood re-circulation of the engrafted liver) was 25 
± 3 minutes in the HALTx-A group and 25 ± 1 minutes in the HALTx-nonA 
group. 
Analysis of Bile Production 
Six HALTx recipients in each experimental group were used to evaluate 
intra-operative bile secretion. Immediately after the blood re-circulation of 
the engrafted liver, a tubing of PE-50 was cannulated into the graft common 
bile duct. The bile production of the initial 15 minutes after re-perfusion was 
disregarded to obtain a stabilised outflow. Thereafter, the bile was collected 
at 15-minute intervals up to 60 minutes. All the samples were then frozen for 
the analysis of bilirubin concentration, which was expressed as bilirubin 
excretion (µg/min/g liver). 
Measurement of DNA Synthesis Rate 
DNA synthesis rate was measured as an index of liver regeneration response 
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on post-operative day 1, 2, 3, 7 and 14. At each time point, 8 HALTx 
recipients of each experimental group were sacrificed under ether 
anaesthesia. 3[H] thymidine (specific activity 26 Ci/mmol, Nycomed 
Amersham plc, England) of 0.2 mCi/g body weight was injected 
intravenously 2 hours before sacrifice. The patency of the hepatic arterial 
anastomosis, whenever relevant, was examined. The liver was then flushed 
with cold physiological saline via the portal vein. The right lobes of the 
engrafted liver were frozen in liquid nitrogen for determining the DNA 
synthesis rate by the incorporation rate of 3[H] thymidine into nuclear DNA, 
while the left lobes and the recipient’s native livers were kept in formalin for 
histological evaluation. The DNA fraction was extracted following the 
procedures described elsewhere [15]. The radioactivity of 3[H] thymidine 
was measured in a liquid scintillation counter and the DNA concentration of 
the same homogenate was determined by the standard method of 
colorimetric readings at 700 nm, using calf thymus DNA (Boehringer 
Mannheim GmbH, Germany) as the standard. The DNA synthesis rate was 
expressed as d.p.m. x 10-3/µg DNA. 
Post-operative Follow-ups 
Twelve rats in each group were used to evaluate post-operative liver biology, 
graft and animal survival. Blood samples were taken on post-operative day 1, 
2, 3, 7 and weekly thereafter. Serum alanine aminotransferase activity 
(ALAT), total bilirubin concentration (TBil) and gamma glutamyl 
transferase activity (GGT) were measured using routine photometric tests on 
a Hitachi 747 analyser. An autopsy was performed whenever a rat died and 
all the long-term survivors were sacrificed at the end of the third post-
transplant month for histological examination. The liver samples were fixed 
in 10% formalin. Four-micron thick sections were stained with hematoxylin 
and eosin (HE) or trichrome and examined under light microscope. 
Statistics 
The data were expressed as the mean ± standard deviation (SD). The 
distribution of the data was checked by Kolmogorov test. The Student's t-test 
or the Mann-Whitney rank sum test was applied for normally or not-
normally distributed data, respectively. P values equal to or less than 0.05 
were considered statistically significant. 
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Table 1.  Intra-operative bile flow rate and bilirubin excretion of the engrafted 
liver after reperfusion in the HALTx-A and HALTx-nonA groups 
 HALTx-A 
(n = 6) 
HALTx-nonA 
(n = 6) 
p 
Bile flow rate (µl/min/g liver)    
 15 min 1.65 ± 0.09 0.97 ± 0.13 < 0.001 
 30 min 1.78 ± 0.27 0.97 ± 0.10 < 0.001 
 45 min 1.84 ± 0.30 0.99 ± 0.09 < 0.001 




0.06 ± 0.02 
 
0.02 ± 0.01 
   
0.007 
Note: Data are expressed as mean ± SD. 
RESULTS 
Intra-operative Bile Production 
As shown in the Table 1, immediately after the blood re-circulation through 
the engrafted liver, the bile flow rate of the grafts with re-arterialisation was 
significantly higher than that of the non re-arterialised grafts (1.65 ± 0.09 vs. 
0.97 ± 0.13 µl/min/g liver, p < 0.001). This remained throughout the 
observation period of 60 minutes (p < 0.001). During this period, the mean 
bilirubin excretion of the HALTx-A group was more than 3 times higher 
than that of the HALTx-nonA group (0.06 ± 0.02 vs. 0.02 ± 0.01 µg/min/g 
liver, p = 0.007). 
DNA Synthesis Rate 
In the two experimental groups, the incorporation rate of 3[H] thymidine into 
nuclear DNA increased after the transplantation and showed a peak value on 
the post-operative day 2. The mean value of DNA synthesis rate in the 
HALTx-A group was significantly higher than that in the HALTx-nonA 
group (791 ± 113 vs. 471 ± 151 d.p.m. x 10-3/µg DNA, p < 0.001). These 
peak values fell sharply after day 2 and reached residual low levels on day 7. 
DNA synthesis rates remained steady thereafter with however progressive 
decline in the non re-arterialised group. On day 14, the values of the 2 
groups were 149 ± 45 (HALTx-A) and 87 ± 24 (HALTx-nonA) d.p.m. x 10-
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3/µg DNA (p < 0.05) Figure 2. Post-HALTx course of DNA synthesis rate of 
the engrafted livers (mean ± SD) in the re-arterialised group (HALTx-A) and 
the non re-arterialised group (HALTx-nonA). * p < 0.05, *** p < 0.001. 
(Figure 2). 
Post-operative Follow-ups 
In the HALTx-A group, 9 out of 12 rats survived the observation period of 
three months. One rat died of cholangitis, and another 2 died of abscesses 
and parenchymal necrosis in the engrafted liver, the latter of which was due 
to thrombosis of the portal vein and the vena cava. Among the 12 HALTx-
nonA rats, 6 died during the follow-up period. Post-mortem examination 
revealed cholangitis in 3 rats and complete necrosis of the engrafted livers in 
another 3. This resulted in a 3-month survival rate of 75% in the HALTx-A 
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Figure 3. Three-month survival rate after HALTx with graft re-arterialisation 
(HALTx-A) and without graft re-arterialisation (HALTx-nonA). 
After the transplantation, the levels of serum ALAT activity were elevated in 
the rats of both groups on day 1 and declined on day 2. Thereafter, the mean 
values of the re-arterialised rats remained in the normal range, while the rats 
of the HALTx-nonA group showed drastically increased values. The 
differences between the HALTx-A and HALTx-nonA group were significant 
on post-operative day 2 (24 ± 10 vs. 54 ± 18 U/l, p < 0.05), day 3 (45 ± 18 
vs. 115 ± 36 U/l, p < 0.05) and day 7 (35 ± 7 vs. 111 ± 56 U/l, p = 0.01) 
(Figure 4a). The post-operative serum TBil concentration increased in the 
rats of both groups and, however, the re-arterialised rats had lower mean 
TBil values and sooner normalisation compared with that of the rats of the 
other group. On day 7, the re-arterialised rats had a mean TBil value of 0.11 
± 0.03 mg/dl, which was significantly lower than 0.17 ± 0.04 mg/dl of the 
non re-arterialised rats (p = 0.01) (Figure 4b). Serum GGT activity showed 
even more pronounced differences: mean GGT activity of the rats in the 
HALTx-nonA group was 5 times higher than that of the re-arterialised rats 
on the post-operative day 3 and 7. GGT activity of the re-arterialised group 
was only slightly elevated after transplantation, while this parameter was 
profoundly altered in the other group (day 3, 0.8 ± 0.9 vs. 5.8 ± 2.9 U/l, p < 
0.001; day 7, 1.1 ± 1.3 vs. 5.9 ± 2.9 U/l, p = 0.002 and day 14, 1.0 ± 1.3 vs. 
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Figure 4. Post-HALTx evolution of serum ALAT (mean ± SD; a), TBil (b) and 
GGT (c) in the HALTx-A group and the HALTx-nonA group. * p  0.05, ** p < 
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a. 
b. 
Figure 5. Histological observations. (a) A rat of HALTx-A group sacrificed 3 
months after the transplantation: the general lobular architecture of the 
engrafted liver was well preserved with a patent hepatic artery (Trichrome 
staining, original magnification x 100). (b) A rat of HALTx-nonA group 
sacrificed at the end of 3rd post-transplant months: the general architecture of 
the engrafted liver was completely destroyed and replaced by massive ductal 
metaplasia. Only remnants of hepatocytes were rarely seen around the portal 
tract (Trichrome staining, original magnification x 100). 
At the end of the 3-month follow-up period, amongst 9 long-term survivors 
of the HALTx-A group, five showed enlarged grafts with well-preserved 
general lobular architecture (Figure 5a), while their native livers were 
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atrophic. The engrafted livers of the other 4 rats were remained unchanged in 
size or smaller. Portal vein thrombosis was found in one case and intra-
hepatic or intra-peritoneum abscesses were present in the other 3 rats. In 
contrast, the atrophy of the engrafted liver was found in 5 out of 6 long-term 
survivors in the HALTx-nonA group, while their native livers appeared 
normal. Histology revealed that massive ductular metaplasia altered the 
general architecture of those engrafted livers (Figure 5b). Only one graft did 
not show complete atrophy (engrafted liver: 4.1 g; native liver: 6.7 g) and in 
this case the engrafted liver had contracted extensive adhesions with the 
omentum. 
DISCUSSION 
After a long-lasting debate, the importance of re-arterialisation for the rat 
model of orthotopic liver transplantation has generally been accepted. The 
possible impact of graft re-arterialisation on the rat model of HALTx was 
investigated in the present study with special focus on immediate graft 
function and post-transplant regenerative response. 
The influence of re-arterialisation on early graft function was assessed by the 
initial intra-operative bile production after re-perfusion of the engrafted 
liver. This parameter is known to be more indicative for early post-operative 
hepatic function than standard liver biology [16]. Since bile production is an 
ATP and an O2-dependent process [17], it is expected that the hepatic artery 
should play an important role by maintaining an appropriate intra-hepatic 
pO2. The data of this study show that indeed the re-arterialisation of the 
engrafted liver leads to a significantly higher quantity and quality of bile 
production of the graft indicating an improved early graft function. 
Post-operative biliary complications following non re-arterialised orthotopic 
liver transplantation were previously attributed to poor surgical technique 
rather than the lack of the hepatic artery re-construction [18]. Later on, it 
appeared that it was spontaneous post-transplant graft re-arterialisation that 
compensated the absence of initial artery supply, which might be accounted 
for the reported high success rates and an almost normal histology. The 
development of spontaneous graft re-arterialisation through adhesions of the 
omentum and the surrounding organs is however a slow process. The earliest 
sign of collateral arterial blood flow recorded by microspheres as well as by 
angiography in non-arterialised liver grafts was not seen before the third 
post-transplant week [19]. Only until the 8th week, significant re-
arterialisation could be evidenced by histology, while the regression of bile 
duct damage and the regression of bile duct proliferation were accomplished 
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6 months after the transplantation [20]. Using magnetic resonance imaging, 
we observed that in the rat HALTx, the healthy engrafted livers could 
already be distinguished from those that would develop post-operative 
complications (including biliary obstruction) and eventually atrophy as early 
as in the first post-transplant week (un-published data). This indicates that in 
the HALTx model the early graft function is crucial for long-term graft 
survival, since the possible recuperation of the engrafted liver is conditioned 
not only by the degree of initial hepatic damage but also by proper balance in 
the inter-liver competition. If a functional advantage is even temporarily 
given to the native liver, spontaneous graft re-arterialisation, which may 
occur at a later stage, will not be able to reverse the ongoing graft atrophy. 
As for the orthotopic transplantation [6, 9], the current results emphasize the 
importance of re-arterialisation for reducing biliary complications and 
consequent graft failure in the HALTx model. 
The data of the present study also showed that, with or without hepatic artery 
supply, regeneration was transiently stimulated in the engrafted livers 
following a HALTx. This increase in DNA synthesis rate was presumably 
due to a “first pass” of portal hepatotrophic factors flowing through the 
partial hepatectomized graft. The 24-hour delay of the initial peak compared 
with that after a standard two-third partial hepatectomy [21] could be due to 
ischemic damage and operative stress [22]. Remarkably, the re-arterialised 
rats revealed a more pronounced regenerative response than the non re-
arterialised rats despite equivalent portal blood supply. As the donor and 
recipient rats were syngeneic and the ischemic time was comparable between 
the two experimental groups in this study, neither acute rejection [23] nor 
ischemic damage [24] could explain these recorded differences. Thus, it was 
the re-arterialisation that directly enhanced the first regeneration boost in the 
engrafted livers. It is known that warm ischemia during the transplantation 
procedures causes depletion of ATP, which directly induces damage to the 
hepatocytes [25] and impairs the general hepatic functions such as protein 
synthesis and bile secretion [26]. The initial regeneration response is also 
depressed [22]. Re-arterialisation does improve the hepatic oxygen supply 
needed for an increased ATP synthesis in the liver graft [8], so that the 
significantly high DNA synthesis rate shown in the re-arterialised rats of this 
study may directly be attributed to reduced warm ischemic injury of the 
engrafted liver. 
The elevated regenerative response however did not persist as seen in the rats 
subjected to a two third partial hepatectomy or as recorded in the orthotopic 
liver transplantation model [27] and fell to low levels immediately after the 
initial peak. In orthotopic liver transplantation, a loss of the functional 
hepatocytes caused by cellular necrosis does continue to stimulate 
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regeneration, whereas in HALTx, the remaining recipient’s native liver may 
compensate in case of a deficient graft function. In addition, this model is 
remarkable by the fact that after the transplantation the total amount of 
hepatic mass exceeds the pre-transplant normal liver volume. This could 
explain the “switch-off” phenomenon of proceeding regenerative process in 
the engrafted liver. The present results suggest that it takes more than a “first 
pass” of portal stimulating factors to maintain regeneration. Whether the 
“switch-off” is due to an increase of specific inhibitory factors or a reduction 
of stimulating factors circulating through the graft remains to be clarified. 
The rat model of HALTx may serve as a useful tool to study this 
phenomenon regularly seen in clinical HALTx and oversized liver 
transplantation. This oversized liver model may thus provide new paths to 
gain further insight into the complicated mechanisms of liver regeneration. 
Atrophy of the engrafted liver in the HALTx was first recognised as such by 
Starzl and his co-workers [1]. As this atrophy could be prevented by portal 
vascularization of the graft [2], the maintenance of portal supply is 
considered the prime factor for the preservation of graft integrity. In turn, the 
hormonal hepatotrophic factors are regarded as the key elements in the inter-
liver competition of HALTx. This study shows that in this oversized HALTx 
model, without re-arterialisation, graft survival can not be guaranteed by a 
sole portal blood supply. The functional position of the engrafted liver in the 
balance of inter-liver competition is another important factor determining 
graft regeneration. In addition, the current study demonstrates that re-
arterialisation of the engrafted liver can not only significantly enhance the 
general function of the engrafted liver such as improved bile production and 
reduce post-operative biliary complications, but also induce a strong post-
transplant regenerative response. A better graft and animal survival could 
then be obtained as compared with non re-arterialised model. We may thus 
conclude that the re-arterialisation of the engrafted liver indeed plays an 
important role to prevent graft atrophy and should be considered as necessity 
in this rat model of HALTx. 
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SUMMARY 
Although portal venous supply is considered essential to preserve hepatic 
integrity, in this study, effects of portal arterialisation on liver regeneration 
were evaluated in a rat model of partial hepatectomy. Ninety-six Lewis rats 
were randomly assigned to four groups of twenty-four each: partial 
hepatectomy only (group 1), partial hepatectomy with either venous or 
arterialised portal supply (groups 2 and 3, respectively), and partial 
hepatectomy without portal supply (group 4). Liver regeneration rate, 5-
bromo-2-deoxyuridine (BrdU) labelling index, and liver biological 
characteristics were assessed on days 1, 2, 3 and 7. Compared with group 1, 
all the tested rats had a marked body weight loss after surgery, and only the 
rats in group 4 showed no signs of recovery on day 7. With maintained 
portal inflow (groups 1, 2, and 3), liver regeneration rate increased steadily 
to day-7 values of 89.2 ± 11.8%, 81.4 ± 8% and 77.4 ± 9.4%, respectively (p 
= not significant), and 24-hour peak values of BrdU labelling index were 159 
± 26, 157 ± 42, and 149 ± 48, respectively (p = not significant). Conversely, 
the rats deprived of portal supply (group 4) showed profound inhibition of 
these two parameters (14 ± 13, p < 0.01; 32.1 ± 7.7%, p < 0.001, 
respectively). These results indicate that proper portal blood supply is 
essential to initiate and maintain liver regeneration after partial hepatectomy. 
With an equivalent portal inflow rate of either venous or arterial source, the 
hepatic regeneration response can be sustained. 
Liver Transplantation 2002; 8(2):146-152 
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INTRODUCTION 
The concept of arterialisation of the portal vein has drawn a constant 
attention since the 1960s because of its various clinical applications. In an 
attempt to reduce post-shunt encephalopathy, portal arterialisation was first 
used clinically in combination with an end-to-side portosystemic shunt to 
treat patients with liver cirrhosis.1-3 Because the increased oxygen supply 
after portal arterialisation can improve hepatic energy metabolism and liver 
regeneration, a technique of partial arterialisation has also been favoured in 
extended hepatectomy for patients with advanced hepatobiliary malignancy.4 
Temporary use of portal arterialisation during liver transplantation surgery 
has shown beneficial effects on shortening warm ischemia time of the donor 
liver and consequently reducing the incidence of immediate post-operative 
graft failure.5, 6 In the case of extensive portal and splanchnic vein 
thrombosis, or absence of the portal and mesenteric vein because of anatomic 
variations, portal arterialisation is an option to preserve sufficient hepatic 
blood supply in orthotopic liver transplantation.7-11 More recently, 
encouraging results have been reported with the use of this procedure in 
heterotopic auxiliary liver transplantation to treat patients with acute liver 
failure.12 
The quality of the portal venous inflow has generally been regarded as the 
key elements for the preservation of hepatic integrity.13-15 With a relative low 
concentration of hormonal hepatotrophic factors, an arterialised portal 
supply would hamper the regeneration capacity of the liver. In the present 
study, liver growth and DNA synthesis rate were compared among rats with 
either venous or arterialised portal inflow, or without portal supply after 
partial hepatectomy. The post-operative evolution of body weight and liver 
biological characteristics was also analysed. A modified technique of 
arterial-venous anastomosis was used to obtain an arterialised portal supply 
with an inflow rate similar to that of portal venous supply following partial 
hepatectomy. 
MATERIALS AND METHODS 
Experimental Animals 
Male inbred Lewis rats (IFFA CREDO Belgium sa, Brussels, Belgium), 
weighing 240-300 g, were used in this study. Animals received humane care 
according to European guidelines (Het Belgisch Staatsblad, Feb. 29th, 1992). 
All animals were kept in a temperature-controlled environment with a 12-
hour light-dark cycle and had free access to food and water. After an 
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acclimation period of one week, all rats were fasted for 12 hours before 
surgery. 
Ninety-six rats were randomly assigned into four groups of twenty-four rats 
each. A standard 68% partial hepatectomy was performed in the rats of all 
four experimental groups to induce liver regeneration. In group 1, only 
partial hepatectomy was performed. In group 2, with the exception of a 
period of portal vein occlusion to reproduce the transitory splanchnic 
congestion similar to group 3, portal venous supply of the liver remained 
intact. In group 3, portal supply of the liver was arterialised through an 
arterial-venous anastomosis. In group 4, portal supply of the liver was 
completely by-passed by a portacaval shunt. 
Surgical Procedure 
Under ether anaesthesia, all the operations were performed using clean but 
non-sterile instruments. A heating pad was used to maintain a stable body 
temperature at approximately 36°C throughout the surgery. 
A 68% partial hepatectomy (68% PH) was performed according to the 
technique described by Higgins and Anderson.16 Through a midline incision, 
the median and the left lobes of the liver were excised after placement of a 5-
0 suture ligature on the corresponding pedicle. Rats of all groups were also 
subjected to a right nephrectomy, which was needed for portal arterialisation 
in group 3. In the rats of group 2, after a 68% PH, the portal vein was cross-
clamped for a period of ten minutes (equivalent to the average time needed to 
perform portal vein arterialisation in the rats of group 3). A portacaval shunt 
(PCS) was placed in the rats of group 3 and 4 using the technique introduced 
by Lee and Fisher:17 after dividing the pyloric vein, the portal vein was ligated 
and transsected. Using hand-sutured technique, the distal part of the portal vein 
was anastomosed to the vena cava in an end-to-side manner. Arterialisation of 
the portal vein (PVA) in the rats of group 3 was performed with the stent 
technique: after a right nephrectomy, a polyethylene tubing (24 Ga) of 0.6 
cm was interposed between the right renal artery and the proximal part of the 
portal stump, and then secured with a 5-0 suture. This technique had the 
advantage of allowing arterial-venous anastomosis to be conducted with a 
stable inflow rate by using a stent with a standard inner diameter. It was 
measured in our laboratory that, through a stent of 24 Ga (0.5 mm inner 
diameter), the average flow rate of an arterialised portal supply was between 
8 ± 3 ml/min and 9 ± 3 ml/min, which was similar to the recorded portal 
venous inflow after a 68% PH (7 ± 2 ml/min, minimum; 8 ± 2 ml/min 
maximum). The peritoneal cavity was closed in two layers. 
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At the end of operation, 1.5 cc of heparinized physiological saline solution 
was transfused intravenously and 10 mg Na Cefazolin was injected 
intramuscularly. The pre-operative diet of food pellets were resumed two 
hours after operation. 
Assessment of Liver Regeneration 
Six rats from each group were sacrificed on the post-operative day 1, 2, 3 
and 7. One hour before sacrifice, all examined rats were weighted and 5-
bromo-2-deoxyuridine (BrdU, 50 mg/Kg body weight) was injected 
intraperitoneally. Each liver was removed and immediately weighed. The 
ratio of liver weight to body weight (LW-BW) was calculated. From the 
resected liver weight at surgery and the remnant liver weight at autopsy, the 
liver regeneration rate (LRR) was determined according to the formula of 
Child:18 
 (liver weight at autopsy – estimated residual liver weight 
 at the time of surgery) 
x 100% 
 resected liver weight 
The resected liver specimens were fixed in 4% formalin. Five-micron thick 
sections were stained with haematoxylin and eosin for light microscopic 
examination. To allow calculation of BrdU labelling index, an indicator for 
DNA synthesis in hepatocytes, immunohistochemical staining of 
incorporated BrdU was obtained using Ventana system (Ventana Medical 
Systems, Inc. Tucson, Arizona, USA). After deparaffinization, the sections 
were sequentially treated with inhibitor for four minutes and protease 1 for 
six minutes. The sections were then incubated with monoclonal IgG1 anti-
BrdU antibodies (Medical  biological laboratories co., Naka-ku Nagoya, 
Japan) for thirty-two minutes, after which they were incubated consequently 
with amplifier A, amplifier B, biotinylated Ig, avidin-hrpo, AEC and AEC 
H2O2 for eight minutes each. The sections were counterstained using 
haematoxylin for six minutes and bluing reagent for two minutes. All steps 
were carried out at the temperature of 37C. Hepatocytes containing nuclei 
with brown staining were considered labelled. The number of positive 
stained cells was counted in randomly selected fields of ten each in 
periportal, midzonal and centrolobular areas using high-power fields 
(original magnification x 320). The number of BrdU-labelled nuclei per 
1000 hepatocytes was designated as the BrdU labelling index. 
Liver Biochemical Tests 
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At sacrifice, blood samples were drawn from the inferior vena cava. Serum 
alanine aminotransferase activity (ALAT) and albumin concentration (Alb) 
were analysed for subsequent assessment of hepatic injury and liver function, 
respectively.  
Statistics 
Data were expressed as mean ± standard deviation (SD). Data distribution 
was checked by the Kolmogorov test. The Student's t-test or the Mann-
Whitney rank sum test was applied for normally or not-normally distributed 
data, respectively. P value of 0.05 or less was considered statistically 
significant. 
 
Figure 1. Body weight ratio (BWR) 1, 2, 3 and 7 days after 68% partial 
hepatectomy. Compared with the control rats (group 1, ), on day 2 and 3, 
the rats either with portal inflow (venous, group 2, ; arterialised, group 3, ) 
or without portal inflow (group 4, ) had marked body weight loss. On day 7, 
only the rats deprived of portal supply (group 4, ) showed no signs of 
recovery. (n = 6 each group). Values were expressed as mean ± SD. 
Asterisks indicated statistically significant differences between the 
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RESULTS 
Body Weight 
Post-operative changes in body weight were expressed as the ratio to the 
initial value immediately after surgery (day 0) (BWR). As shown in Figure 1, 
the mean BWR of the rats subjected to partial hepatectomy (group 1) 
increased steadily from -4.06 ± 1.89% on day 1 to 4.35 ± 2.97% on day 7. 
The different surgical manipulations in the rats of group 2 and 3 showed 
similar effects on BWR evolution: BWR values of these two groups declined 
during the first three days after surgery. They were significantly lower than 
that of group 1 on the second (p < 0.01, group 2 and 3) and the third post-
operative day (p < 0.01; p = 0.001, respectively). On day 7, though the 
values of group 2 and 3 were still lower than that of group 1 (p < 0.01, group 
3), they nearly recovered from the initial loss, and the difference between 
these two groups was not significant. Without portal blood supply, however, 
the mean BWR value of the rats in group 4 remained at a low level even 
seven days after surgery (-9.09 ± 1.35%), which was significantly lower than 
the three other groups (4.35 ± 2.97%, 0.83 ± 3.37%, -2.42 ± 1.93%, 
respectively; p < 0.001). 
Ratio of Liver Weight to Body Weight (LW-BW) 
After the operation, the mean LW-BW value of the rats in group 1 rose from 
1.57 ± 0.1% on day 1 to 2.93 ± 0.18% on day 7, an increase of 213% from 
its initial value of 0.94 ± 0.08% (day 0). A sharp increase of LW-BW was 
also observed in the rats of both group 2 and 3: from the day-1 value of 1.57 
± 0.13% (group 2) and 1.50 ± 0.13% (group 3), they reached 2.73 ± 0.19% 
and 2.69 ± 0.20% on day 7, which corresponded to a 180% and 177% 
increase from the initial values (0.98 ± 0.06%, 0.97 ± 0.04%, respectively). 
Compared with those of group 1, the values of group 2 and 3 were 
significantly lower on day 2 (p < 0.001, group 2; p < 0.01, group 3) and day 
3 (p = 0.001 group 2), whereas the differences were no longer significant on 
day 7. No marked differences could be recorded between the values of group 
2 and 3. In the absence of portal supply, the rats of group 4 showed the 
lowest increase rate of LW-BW among the four groups. Throughout the one-
week observation period, the LW-BW values of group 4 were markedly 
lower than those of the other three groups (p < 0.001). On day 7, the value of 
1.80 ± 0.2% was only an increase of 94% from its initial value of 0.93 ± 
0.03% (Figure 2). 
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Figure 2. Ratio of liver weight to body weight (LW-BW) 1, 2, 3 and 7 days 
after 68% partial hepatectomy. Compared with the control rats (group 1, ), 
the increase of LW-BW was slower in the rats with either venous portal inflow 
(group 2, ; day 2 and 3) or arterialised portal inflow (group 3, ; day 2). 
Throughout the one-week observation period, LW-BW in the rats deprived of 
portal supply (group 4, ) was significantly lower than those in the rats of 
other groups. (n = 6 each group). Values were expressed as mean ± SD. 
Asterisk indicated statistically significant differences between the 
experimental groups. ** p < 0.01; *** p < 0.001. 
Liver Regeneration Rate (LRR) 
As shown in Figure 3, hepatectomised livers regenerated at a similar rate in 
the rats of group 1, 2 and 3 during the first post-operative week. From the 
day-1 values of 26.3 ± 4.8% (group 1), 24.8 ± 8.9% (group 2) and 23.7 ± 
5.8% (group 3), LRR values increased to 89.2 ± 11.8%, 81.4 ± 8% and 77.4 
± 9.4% on day 7, respectively. No significant differences were found among 
the values of these three groups. Complete portal by-pass in the rats of group 
4 hampered liver regeneration profoundly: compared with those of group 1, 
2 and 3, the respective LRR values of group 4 were significantly lower on 
day 1 (p ≤ 0.01), day 2 (p < 0.001) and day 3 (p ≤ 0.001). On day 7, the 
value of 32.1 ± 7.7% in the rats of group 4 was 64%, 61% and 59% less than 
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Figure 3. Liver regeneration rate (LRR) 1, 2, 3 and 7 days after 68% partial 
hepatectomy. Similar to the control rats (group 1, ), the rats with persistent 
portal inflow (venous, group 2, ; arterialised, group 3, ) had significantly 
higher liver growth than the rats deprived of portal supply (group 4, ) during 
the first post-operative week. (n = 6 each group). Values were expressed as 
mean ± SD. Asterisk indicated statistically significant differences between the 
experimental groups. * p ≤ 0.05; ** p < 0.01; *** p < 0.001. 
BrdU Labelling Index 
Immunohistochemical staining for BrdU in livers of the four experimental 
groups is shown in Figure 4. The post-operative evolution of BrdU labelling 
index was similar in the rats of group 1, 2 and 3: the number of positively 
stained cells peaked twenty-four hours after PH (159 ± 26, 157 ± 42 and 149 
± 48, respectively) and declined thereafter. Differences among these three 
groups were not significant. In contrast, the BrdU index was drastically 
suppressed in the rats without portal blood supply. The recorded 24-hour 
value of 14 ± 13 in the rats of group 4 was less than one tenth of those in the 
rats of the other three groups (p < 0.001, compared with group 1 and 2; p < 
0.01, with group 3). On day 2, it was still significantly lower than those of 
other groups (p < 0.001, compared with group 1 and 2; p < 0.05, with group 
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Figure 4. Immunohistochemical staining for 5-bromo-2-deoxyuridine (BrdU) 
24 hours after 68% partial hepatectomy. Similar to the control rats (group 1, 
A), the rats with persistent portal inflow (venous, group 2, B; arterialised, 
group 3, C) had a significantly higher percentage of BrdU-positive staining 
hepatocytes (nuclei with deposition of brownish pigment) than the rats 
deprived of portal supply (group 4, D). (original magnification x 400). 
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Figure 5. 5-bromo-2-deoxyuridine (BrdU) labelling index on 1, 2, 3 and 7 
days after 68% partial hepatectomy. On day 1 and 2, similar to the control 
rats (group 1, ), the rats with persistent portal inflow (venous, group 2, ; 
arterialised, group 3, ) had a significantly higher percentage of BrdU-
positive staining hepatocytes than the rats deprived of portal supply (group 4, 
). (n = 6 each group). Values were expressed as mean ± SD. Asterisk 
indicated statistically significant differences between the experimental groups.  
* p ≤ 0.05; ** p < 0.01; *** p < 0.001. 
Liver Biochemical Tests  
The mean values of serum albumin concentration decreased in the rats of all 
four groups after surgery (Table 1). Serum albumin concentration (Alb) of 
the rats in groups 1, 2 and 3 recovered one week later and no marked 
differences were found among the values of these three groups. Without 
portal supply, the rats of group 4 showed a prolonged decrease in serum Alb 
levels, and the value of 2.7 ± 0.3 on day 7 was significantly lower than the 
level of 3.2 ± 0.3 of group 1 (p = 0.01). The mean levels of serum alanine 
aminotransferase activity (ALAT) peaked one day after surgery in all rats of 
the four groups and declined thereafter. Compared with the value of group 1, 
significantly higher ALAT levels were found only in group 3 on day 2 (p < 
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DISCUSSION 
The importance of portal blood supply to regeneration of the liver has been 
noted since the 1920s, based upon the observation that total liver mass and 
hepatocyte number are larger with intact portal inflow and atrophy occurs in 
liver deprived of portal venous blood.19 It is further evidenced as such by the 
discovery that a liver lobe transplanted in an auxiliary position will 
regenerate, if the engrafted liver instead of the native liver receives the portal 
blood.20, 21 The data from the current study clearly show that adequate portal 
inflow is essential for liver regeneration after a partial hepatectomy. 
Corresponding well with previous reports,22, 23 complete diversion of portal 
blood realised by a portacaval shunt not only results in prolonged post-
operative body weight loss, but also delays or abolishes the expected sharp 
increase in DNA synthesis induced by a standard 68% partial hepatectomy 
and impairs the restoration of the liver mass. Absence of portal flow induces 
hepatocyte degeneration characterized by cell volume decrease and cell 
death,24 and deprives of the portal hepatotrophic factors. 25, 26 These may be 
responsible for the hampered regeneration capacity. On the other hand, a 
significant decrease in total portal inflow is known to lead to a rapid increase 
Table 1. Post-operative evolution of serum albumin concentration (Alb) and 
alanine aminotransferase activity (ALAT) 
 Day -1 Day 1 Day 2 Day 3 Day 7 
Alb (g/dl) 3.3 ± 0.2     
group 1 (n = 6)  2.9 ± 0.2 3.0 ± 0.2 3.0 ± 0.5 3.2 ± 0.3 
group 2 (n = 6)  2.7 ± 0.2 2.8 ± 0.3 3.0 ± 0.3 3.0 ± 0.3 
group 3 (n = 6)  2.7 ± 0.1 2.8 ± 0.2 2.7 ± 0.2 2.9 ± 0.3 
group 4 (n = 6)  2.9 ± 0.2 2.8 ± 0.2 2.7 ± 0.3   2.7 ± 0.3* 
ALAT (U/l) 41 ± 9     
group 1 (n = 6)  292 ±  62   109 ± 37 68 ± 17 56 ±   7 
group 2 (n = 6)  360 ± 188   130 ± 87 65 ± 11 49 ±   9 
group 3 (n = 6)  357 ±  59 156 ± 47* 62 ± 19 54 ± 11 
group 4 (n = 6)  454 ±  70**   131 ± 24 54 ±   7 50 ± 26 
Note: Values were expressed as mean ± SD. Asterisk indicated statistically 
significant differences versus the values of group 1. * p  0.05; ** p < 0.01. 
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in the blood flow in the hepatic artery, through which general liver function 
can be sustained.11, 27 However, the data from this study reveal that, deprived 
of portal supply, the peak value of DNA synthesis rate is reduced to one 
tenth of the expected normal value, and liver regeneration rate one week 
after partial hepatectomy is only one third of that recorded in the rats with 
normal portal supply. This finding may indicate that the degree of the 
compensation from the hepatic artery is insufficient to initiate a proper 
hepatic regeneration response and maintain the regenerative process after 
partial hepatectomy, which would confirm the theory that this compensatory 
mechanism of the so-called hepatic artery buffer response is only partial.28, 29 
To date, much speculation exists, in particular, on whether the quality of the 
portal blood (contents) or the quantity of the portal blood (inflow rate) is of 
major importance for liver regeneration. It is suggested that the diversion of 
hormonal hepatotrophic factors, such as endogenous insulin, from the portal 
tract to the systemic circulation, is responsible for the atrophy seen after 
portal shunt.14, 30 Conversely, other investigators have shown that when the 
portal tract is perfused by systemic venous blood rather than the blood 
flowing from the intestines and pancreas, liver size can be maintained18, 31 
and regenerative hyperplasia is within the normal range.32 The evidence in 
this study that hepatic regeneration response can be initiated, even with an 
arterialised portal supply after a partial hepatectomy, further supports the 
later argument. Moreover, when the inflow rates are equivalent, the 
hepatectomised livers with an arterialised portal supply can regain their 
weight as fast as those with a portal venous supply. By separately measuring 
hepatic venous and arterial inflow (per gram of tissue mass) after a left portal 
vein stenosis, Rocheleau et al. recently demonstrated that either portal 
venous or hepatic arterial flow could maintain viable liver mass in 
proportion to the amount of blood flow delivered.33 The data from the 
present study may therefore indicate that the initiation and maintenance of 
liver regeneration induced by a partial hepatectomy do not necessarily 
require highly concentrated hepatotrophic factors, or that elements other than 
those classical splanchnic factors may be the initial trigger of the 
regenerative process. 
Based on the discoveries of the last decades, the phenomenon of liver 
regeneration has been defined as a precise and highly orchestrated response 
induced by specific external stimuli, which involves sequential changes in 
morphologic structure, gene expression and growth factor production. 
Although many growth factors and cytokines, such as hepatocyte growth 
factor, epidermal growth factor, transforming growth factor-α, interleukin-6, 
tumour necrosis factor-α insulin, and norepinephrine, appear to play an 
important role in this process, none of these substances seem to be a primary 
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mitogen for hepatocytes.34 It has been realised that before replication, 
hepatocytes have to be sensitised in order to be competent and fully 
responsive to the trophic action of growth factors.35, 36 It is hypothesized that 
this so-called “priming” phase, meaning the transition of hepatocyte from a 
G0 resting state to a G1 replicative state, needs gene activation, and that more 
than one pathway may be involved, which may require growth factors and 
cytokines such as tumour necrosis factor and interleukin 6.37 As the priming 
begins simultaneously in all hepatocytes almost immediately after partial 
hepatectomy,38 one can assume that it may be triggered either by hormonal 
factors already present in the blood or liver, or by hemodynamic factors. In 
parallel to an early and persistent increase in portal pressure,39, 40 researchers 
have found that changes in hepatocyte membrane potential can be recorded 
as early as within five minutes following partial hepatectomy.41 This has 
been linked to a series of alterations that include increases in sodium-
potassium adenosine triphosphatase pump activity, sodium fluxes into 
hepatocytes, and sodium-dependent amino acid transport.38, 42-44 A recent 
report showed that the blood-flow-activated sodium and potassium current in 
cardiac microvascular endothelial cells is flow-rate dependent.45 In addition, 
an increase in portal pressure is also related to such ultra-structural changes 
in the liver as sinusoid dilatation and disappearance of the sieve-plate 
arrangement of small endothelial pores, thus leaving the surface of the 
parenchymal liver cell directly exposed to any circulating hepatotrophic 
substances present in the portal blood.40 We speculate that a significant 
increase in relative blood flow and consequently an even slight increase in 
portal pressure induced by partial hepatectomy may itself be one of the first 
factors triggering the entire process of liver regeneration. Further 
clarification of the exact role of changing portal inflow rate and pressure in 
the priming phase may sort out the earliest signals associated with the 
initiation of the hepatic regeneration response. 
The data from the present study demonstrate that proper blood perfusion in 
the portal tract is essential for initiating and maintaining liver regeneration 
after a partial hepatectomy in the rat. In case of an equivalent inflow rate, the 
immediate hepatic regeneration response can be initiated and the one-week 
liver regeneration rate can be sustained by an arterialised portal supply at the 
same level as by a portal venous inflow. 
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Evaluation of graft viability following heterotopic auxiliary liver 
transplantation 
As assessed in the present work, various surgical manipulations on the 
recipient’s native liver in the rat model of heterotopic auxiliary liver 
transplantation (HALTx) do affect post-transplant animal survival, graft 
survival and liver biology differently. 
Although a normal rat can tolerate a 68% partial hepatectomy (68% PH) 
without major complications, this manipulation becomes a significant 
functional handicap to the liver whose portal supply is completely deprived 
by a portacaval shunt (PCS).1, 2 The partial hepatectomy greatly increases the 
metabolic load at the hepatocellular level,3 while the portal influx of nutritive 
elements needed to response to the high energetic metabolism is totally by-
passed by a PCS.4, 5 This results in an energetic deficit,6 and, consequently, 
hepatic metabolic activities and active biosynthesis of cellular components 
are drastically hampered.2 However, as shown in the current work, with the 
support of an auxiliary liver, the portal deprived native liver can recover 
from this surgical handicap and even take over the engrafted liver to 
regenerate. This indicates that functional reduction of the portal deprived 
liver induced by a 68% PH is still reversible. 
The combined handicap of a 68% PH and a common bile duct ligation 
(CBDL) on a portal deprived liver is so severe not only that hepatic 
regeneration capacity is completely impaired leading to native liver atrophy 
in all long-term HALTx survivors, but also that the rats can not survive this 
handicap without the presence of a functioning auxiliary liver. In this case, 
the post-transplant animal survival relies solely upon the viability of the 
engrafted liver, and the values of serum liver biochemistry therefore reflect 
directly the functionality of the engrafted organ.7 It is recognized that, in 
cholestasis, the intracellular retention of biliary constituents and the 
diminution of bile acids excretion inevitably leads to the imbalance between 
hydrophobic and hydrophilic bile salts in the biliary system.8-10 The known 
hepatotoxic potential of the hydrophobic bile salts, which play a central role 
in the pathogenesis of bile-salt-induced liver injury, is then unmasked.8-12 
Along with high biliary pressure,13, 14 hydrophobic bile salts cause 
hepatocyte death mainly through cytolysis.8, 10 This is characterised by 
morphologic alterations including membrane disruption and cytoplasmic 
enlargement accompanied with increased hepatocellular enzyme release.15-17 
Apoptosis, a form of programmed cell death, has recently been found to be 
the predominant mechanism of hepatocyte death under moderate bile acid 
toxicity.17-19 Hydrophobic bile salts also interfere with the mitochondrial 
function thereby decreasing ATP production,20-22 and inhibit directly 
hepatocyte proliferation 23-25 Furthermore, the activation of Kupffer cells 
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following extra- or intra-hepatic bile duct obstruction is linked to increased  
generation of reactive oxygen species and free-radical formation, which may 
indirectly injure the hepatocytes.26-32 The subsequent activation of hepatic 
stellate cells by Kupffer cells induces the net deposition of collagen and 
other components of the extra-cellular matrix perpetuating liver necrosis, 
fibrosis and cirrhosis.29, 33-37 
Although the damaging effects of this combined handicap of 68% PH and 
CBDL on the native liver is apparently fatal and irreversible, the data of 
post-transplant monitoring by magnetic resonance imaging (MRI) from the 
current work show that, in the presence of a viable auxiliary liver, the 
expected drastic functional decline of the native liver (reflected by T1 
relaxation times) becomes obvious only four weeks after transplantation. 
This new evidence demonstrates that beyond its life-supporting role, a well-
functioning auxiliary liver also reduces the mechanical and the biochemical 
aggression of the handicap imposed on the native liver. This slows down the 
process of the physiological deterioration of the handicapped organ. Liver 
biology, especially during the initial phase after a HALTx, is then a global 
representation of the viability of both the engrafted and the native livers. 
Extra caution should thus be taken when this parameter is used to assess 
graft viability in the rat model of HALTx. Obviously, this specific approach 
cannot be applied in the experimental studies where the survival of the 
native liver is expected, as the imposed inflicted handicap will completely 
abolish its regenerative potential. 
The possible advantages of using MRI to monitor post-HALTx hepatic 
viability are for the first time evaluated and clearly demonstrated in the 
current work. It allows a separate identification of post-transplant 
complications such as abscess and necrosis in the two individual livers. The 
analysis of the relation between signal intensity and hepatic viability brings 
further interesting information. Corresponding well with a previous clinical 
report,38 it is found that the higher the signal intensity on a T1 weighted 
image, the better the hepatic viability. The viability of each individual liver 
can thus be assessed by its signal intensity at any given time. In the current 
work, the post-transplant evolution of T1 relaxation times is compared 
between the healthy engrafted livers and the livers presenting infectious and 
ischemic complications. It reveals that the eventual outcome of the engrafted 
and the native liver, either regeneration or atrophy, can already be predicted 
at an early post-operative stage by examining the pattern of their T1 
evolution. A non-invasive measurement as such can facilitate systematic 
post-transplant follow-up of the evolution of the viability of both livers. MRI 
is hence a very promising tool for the studies on inter-liver functional 
competition. In the situations as pre-surgical evaluation of transplant 
candidates in fulminant or sub-fulminant hepatic failure, and post-transplant 
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or post-hepatectomy assessment of liver viability, the clinical potential of 
MRI could be proved beneficial and indeed warrants further prospective 
human studies. 
Study of inter-liver functional competition following heterotopic 
auxiliary liver transplantation 
After a clinical auxiliary liver transplantation, portal blood supply is shared 
between the engrafted liver and the recipient’s native liver. It has generally 
been accepted that most of the common post-transplant events, such as 
reperfusion injury, allograft rejection, allograft viral infection and native 
liver regeneration, cause changes in intrahepatic portal venous resistance 
modifying the amount of portal blood delivered to the liver. The liver with 
less portal resistance receives more portal blood and consequently 
hepatotrophic factors, and therefore holds a more favourable position in the 
inter-liver competition. In this way, an alteration of the relative portal blood 
distribution will eventually lead to regeneration imbalance between the two 
livers.39-42 
Notably, in the rat model of HALTx used in the current work, the recipient’s 
portal supply is completely shunted towards the engrafted liver, while the 
native liver viability is only sustained by hepatic artery supply. Despite the 
fact that there is no sharing of portal blood between the two livers, a change 
in the degree of surgical handicap on the native liver can still alter the 
outcome of the engrafted organ from regeneration to atrophy; vice versa, an 
improvement of the physiological status of the engrafted liver, as obtained 
by re-establishing its hepatic arterial supply, does result in more pronounced 
native liver atrophy. Unlike in orthotopic liver transplantation (OLTx) where 
the progress of hepatic regeneration relays solely upon the number of viable 
hepatocytes in the newly implanted liver graft, after an auxiliary liver 
transplantation, the regeneration starts immediately in both coexisting livers 
to fulfil the body demand for hepatic metabolic function. If the liver is 
already in a more favourable physiological condition and in addition 
receives optimal portal supply, its regeneration will be advantaged 
preferably by “the first wave” of stimulating growth factors influx delivered 
via the portal tract.41, 43 In parallel to the progressing regeneration of the one 
liver, decreased concentration of those stimulating factors in the blood 
circulation will further bring the other liver into a “dormant” state with 
eventual atrophy. On the other hand, a proper regenerative response cannot 
occur in a liver when its general metabolic function is profoundly hampered 
by either surgical trauma or reperfusion injury, despite proper portal blood 
supply. In this case, regeneration of the other liver, even deprived of portal 
supply, can still be stimulated by the “second wave” of growth factors re-
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circulating through the hepatic artery.44 
In contrary to what is seen in human liver transplantation, re-construction of 
the graft hepatic artery in the rat appears not to be needed for graft and 
animal survival.45, 46 Microscopic studies of the non re-arterialised grafts will 
however reveal a high incidence of bile duct proliferation and biliary 
complications.46-48 Regression of bile duct proliferation and bile duct damage 
is often observed in long-term survival rats, which eventually leads to almost 
normal liver histology.49 The mechanism of this compensation to the lack of 
initial artery supply is mainly attributed to spontaneous graft re-
arterialisation,46, 48-50 which can be seen after the third post-transplant 
week.49, 50 In HALTx, the possible recuperation of the engrafted liver is 
conditioned not only by the degree of initial hepatic damage but also by the 
balance of the inter-liver competition. Good early graft function is hence 
crucial for long-term graft survival in this model. Though the absence of 
arterial supply in the engrafted liver gives, in principle, only temporarily 
functional advantage to the native liver, spontaneous progressive graft re-
arterialisation, which may occur at a later stage, will not be able to reverse 
the ongoing graft atrophy. In addition to the beneficial effects of graft re-
arterialisation reported in previous studies,51-56 the data of the current work 
further reveal that re-arterialisation improves early hepatic function, induces 
a more marked early regenerative response and reduces post-transplant 
biliary complications. The engrafted liver is thus functionally advantaged in 
the inter-liver competition with better graft survival compared with the non 
re-arterialised model. 
Besides stressing the importance of the accessibility of the portal supply with 
its stimulating growth factors and nutritive elements, these results emphasize 
that the coexisting two livers after a HALTx are also competing for the 
regenerative capability based on their physiological status. The balance 
between the supply of regeneration stimulating factors and the hepatic 
capability to response to those factors will determine the final fate of the two 
livers. Up to date, little is known about whether any specific signals are 
transmitted between the two livers to regulate the post-HALTx process. If 
so, further exploration of the nature of those signals will bring more detailed 
insights about the mechanisms of the inter-liver competition phenomenon 
and may also have important clinical implications, in case of acute liver 
failure where temporary functional support of the auxiliary graft is 
required,57 or in case of metabolic diseases where coexistence of two well-
functioning livers is needed.58 
Portal blood supply has been proved to play a vital role in liver 
regeneration. As presented in this work, complete lack of portal supply will 
lead to a significantly impaired regenerative response and restoration of liver 
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mass. When the liver is deprived of its portal vascular blood, hormonal 
growth factors may only reach the liver through the arterial circulation.44 
Through vasodilation, hepatic arterial inflow increases instantly after a PCS 
to compensate the reduction of total liver blood supply. However, the data of 
this work show that the degree of the compensation from this so-called 
“hepatic artery buffer response” is insufficient to restore a proper hepatic 
regeneration response and delays the regenerative process after a standard 
partial hepatectomy. This might be due to the lower concentration of the 
hepatotrophic factors in the arterial blood. Interestingly, it is observed in the 
current work, that with a re-established same amount of blood inflow, the 
hepatic regeneration rate in the hepatectomized rats is equal, irrespective of 
the portal supply of either venous or arterial nature. These data suggest that 
the “required concentration” of hepatotrophic factors may not be essential, or 
rather that the presence of blood in the portal tract itself is a prerequisite of 
initiating and maintaining a normal liver regeneration. This may explain 
why, in ALTx, a liver graft with an arterialised portal supply is sufficient to 
sustain the life of the patient with acute liver failure, while, with an un-
interrupted portal venous supply, the recovery and regeneration of the 
diseased native liver can go on unaffected.59 
Liver regeneration can be induced by a great variety of stimuli ranging from 
dietary alteration, to toxic damage and to loss of liver mass as after partial 
hepatectomy.60 Determining what factors are responsible for initiating the 
regenerative process is one of the core issues in understanding the molecular 
bases of liver regeneration.61 Amongst the so-called “hepatotrophic factors” 
discovered during the last three decades, some growth factors and cytokines 
were hypothesized to be the “initiators”.62-64 Although the role of most of 
those growth regulators has been identified as crucial for a specific step of 
hepatocyte proliferation either as a stimulator or as an inhibitor, none of 
them seems to be a primary mitogen.64, 65 Moreover, it has recently been 
shown that hepatocytes need to be “sensitised” before replicating, which 
means that they have to transit from a G0 resting state to a G1 replicative 
state, in order to be competent and fully responsive to the trophic action of 
the growth factors.66 67 It has been found that this so-called “priming phase” 
begins simultaneously in all resting hepatocytes almost immediately after 
partial hepatectomy.68 As the production of growth factors and cytokines is 
not an immediate event, early hepatic regenerative response following partial 
hepatectomy is more likely to be activated either by hormonal factors 
already present in the blood or in the liver, or by changing hemodynamic 
factors. The most remarkable event instantly occurring after partial 
hepatectomy is the substantial increase of the portal blood flow to the 
residual liver mass with the consequent rise of portal pressure.69, 70 This 
significant hemodynamic change could be one of the first triggers that 
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initiate the regeneration cascade in the hepatectomised liver. Studies have 
shown that, in parallel to an early and persistent increase in portal pressure, 
changes in hepatocyte membrane potential can be recorded as early as within 
the first five minutes after liver resection.71 This is linked to a series of 
events essential for hepatocytes replication.68, 72-74 In addition, following 
partial hepatectomy, consequent alterations in hepatic ultra-structure have 
been documented involving sinusoid dilatation and disappearance of the 
sieve-plate arrangement of small endothelial pores. This leaves the surface of 
the parenchymal liver cell directly exposed to the circulating hepatotrophic 
substances in the portal blood.70 Moreover, an increased portal pressure 
reflecting wall shear stress of sinusoids causes nitric oxide release.75 This 
leads to an increased mRNA expression of c-fos, an immediate-early gene,76, 
77 the protein product of which is known to participate in the stimulation of 
cell growth.78 It has however been shown that, in a portal branch ligation 
model, c-fos as well as other factors such as c-myc, c-jun, NF-B, STAT3 
and IL-6 are similarly induced in both proliferating and atrophying liver 
lobes, and even in the livers of sham operated animals. Only the actual liver 
mass present during the period corresponding to mid- to late G1 phase seems, 
in this case, to determine the magnitude of the proliferative response.79-82 
This could suggest that the observed early regenerative response after liver 
resection is not specifically related to either increased portal flow or loss of 
liver mass; or that still other not yet identified factors are the true 
regenerative triggers. Further clarification on how the hemodynamic changes 
and / or the degree of liver mass reduction modulates the extent of hepatic 
regeneration after partial hepatectomy may elucidate another piece of the 
complex puzzles in the liver regeneration process, which has still kept some 
of its intriguing secrets. 
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SUMMARY 
Although auxiliary liver transplantation does offer advantages over 
orthotopic liver transplantation, in particular in treating patients with acute 
hepatic failure and children with hepatic-based inborn errors of metabolism, 
its results are often compromised by the interactions between the coexisting 
engrafted liver and native liver. To date, it is generally accepted that the 
process and final outcome of the so-called inter-liver competition is 
governed by the supply of portal blood and, most crucial of all, the 
distribution of hormonal “hepatotrophic factors” between the two livers. 
However, other factors such as the physiological status of each individual 
liver might also play an important role in this mechanism. It was, therefore, 
the purpose of the current work, to investigate whether a change in the 
functional condition of each individual liver would influence the fate of the 
two livers using a rat model of heterotopic auxiliary liver transplantation 
(HALTx), and further to re-examine the controversy on whether changing 
the content of the portal blood would alter the hepatic regeneration capacity 
after a standard partial hepatectomy. 
To define indicative biological parameters for post-HALTx evaluation of 
graft viability, a 68% partial hepatectomy (68% PH) and a common bile duct 
ligation (CBDL) were performed to hamper the native liver’s functionality. 
Commonly used serum biochemical liver parameters were analysed. It was 
found that the surgical handicap on the native liver did efficiently induce 
lethal hepatic failure, as, in this case, animal survival relied solely upon the 
viability of the engrafted liver. The liver biology therefore reflected directly 
the graft functionality. The post-operative values of serum bilirubin 
concentration, gamma glutamyl transferase activity, alkaline phosphatase, 
alanine aminotransferase activity and aspartate aminotransferase activity 
were significantly lower in the transplanted rats than in the control rats. 
These data reveal that a viable engrafted liver can indeed reduce the 
deleterious effect of cholestasis caused by the surgical handicap on the 
native liver (Chapter 2.1.). 
In a further study, for the first time, magnetic resonance imaging (MRI) was 
tested for its potential to monitor post-transplant hepatic viability in this rat 
model of HALTx. The results showed, firstly, that post-transplant hepatic 
complications as abscess and necrosis could be depicted separately in the 
coexisting two livers on MR image. Secondly, it was found that the better 
the hepatic viability, the higher the signal intensity on T1 weighted image. 
The viability of each individual liver could thus be assessed by its signal 
intensity at any given time. Thirdly, in the presence of a viable engrafted 
liver, the expected drastic functional decline of the native liver reflected by 
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its T1 relaxation times became obvious only 4 weeks after transplantation. 
This showed clearly the role of the well-functioning auxiliary liver in 
reducing the mechanical and biochemical aggression of the inflicted 
handicap on the native liver. Fourthly, as soon as after the first post-
transplant week, the healthy engrafted livers could already be distinguished 
from those that would develop complications by a significant decrease in T1 
relaxation times. This non-invasive measurement does facilitate systematic 
follow-up of the evolution of the two livers after HALTx. MRI is thus a very 
promising tool for the studies on inter-liver functional competition. 
Prospective human studies based on these new discoveries may further 
demonstrate the beneficial potential of MRI in clinical situations such as pre-
surgical evaluation of transplant candidates in fulminant or sub-fulminant 
hepatic failure and post-transplant or post-hepatectomy assessment of liver 
viability (Chapter 2.2.). 
In order to study specifically the effects of various hepatic physiological 
conditions on the inter-liver competition, the possible influence of portal 
blood distribution to the native liver was abolished by completely shunting it 
to the engrafted liver. This allowed focusing on how the different handicaps 
of the native liver could affect animal survival and the regeneration capacity 
of both the engrafted and the residual native livers. It was observed that a 
viable auxiliary liver was able to prevent high animal mortality caused by a 
68% PH on a portal deprived native liver. The native liver could recover 
from this functional reduction and even regenerate, while the engrafted liver 
atrophied despite its proper portal blood supply. An additional handicap on 
the native liver, through a combined 68% PH and CBDL, resulted this time 
in atrophy of the native liver and regeneration of the engrafted organ 
(Chapter 3.1.). In another experimental setting, the effects of graft re-
arterialisation on liver regeneration were evaluated. It was shown that, the 
re-arterialised grafts had significantly higher bile flow rate and bilirubin 
excretion immediately after re-perfusion compared with that of the grafts 
without re-arterialisation. Re-arterialisation also increased DNA synthesis 
rate of the engrafted liver, and the rat developed less cytolysis and less 
cholestasis. This led to a significantly improved graft growth, which was 
paralleled to a more pronounced native liver atrophy. Re-arterialisation 
could indeed enhance the functional advantage of the engrafted liver 
(Chapter 3.2.). 
In the last part of this work, it was found that complete absence of portal 
blood supply to a partial resected liver caused a marked inhibition of early 
regenerative response and liver growth rate. The degree of the compensation 
from the “hepatic artery buffer response” was insufficient to restore normal 
hepatic regeneration after a standard partial hepatectomy. Notably, if the 
amount of portal blood inflow was re-established by arterialising the portal 
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stump, the DNA synthesis rate as well as liver growth could be sustained at a 
level equivalent to that observed in the rats of control group (Chapter 3.3.). 
The data of the current work emphasize that, besides the portal blood supply, 
the change of the physiological condition of each individual liver does affect 
the balance of the inter-liver competition after a HALTx. Rather than the 
high concentration of the hepatotrophic factors, the presence of sufficient 
blood flow in the portal tract, of either venous or arterial origin, appears a 
prerequisite to maintain the normal chronology and the intensity of the 
regeneration process. 
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SAMENVATTING 
Een auxilliaire levertransplantatie biedt duidelijke voordelen aan bij de 
behandeling van patiënten lijdende aan acuut leverfalen, alsook bij kinderen 
met congenitale metabole ziekten. Ondanks de conceptuele aantrekkelijkheid 
van deze type transplantatie, zijn de resultaten hiervan niet steeds éénduidig 
en dit ondermeer  omwille van het ontstaan van een functionele competitie 
tussen de eigen of natieve lever en de getransplanteerde lever. Vandaag 
wordt het algemeen aanvaard dat de portale bevloeiing van de lever met zijn 
hepatotropische factoren de functionele status van de 2 levers in grote mate 
beïnvloedt. Buiten deze extrinsieke factoren moet men nochtans ook 
rekening houden met levergebonden intrinsieke factoren wanneer gesproken 
wordt over de functionele competitie tussen de 2 levers. De fysiologische 
status van de 2 levers speelt inderdaad een belangrijke rol in het min of meer 
receptief staan van het orgaan ten opzichte van externe stimulatiefactoren. 
Het was dan ook het doel van ons onderzoek om op een rattenmodel van 
heterotope auxilliaire levertransplantatie (HALTx) verschillende functionele 
beperkingen van donor- en recipiëntlevers te testen en na te gaan in welke 
mate deze factoren de competitie tussen de recipiëntlever en de auxilliare 
lever zouden kunnen beïnvloeden. Hiernaast hebben wij ons eveneens de 
vraag gesteld of extrinsieke factoren met dan hier meer expliciet 
hemodynamische factoren implicaties zouden kunnen hebben op de lever 
regeneratie capaciteit na een standaard partiële hepatectomie. 
Om met routine biologische parameters de post-HALTx viabiliteit en functie 
van het getransplanteerd orgaan te kunnen volgen, werd de natieve lever met 
een 68% partiële hepatectomie en galwegen ligatuur belast. Deze 
heelkundige manipulatie van de natieve lever veroorzaakt een dodelijk 
leverfalen in de afwezigheid van een getransplanteerde auxillaire leverent. 
Indien de overleving van de ratten rechtstreeks afhankelijk is van de 
auxilliaire lever, zal de biologie grotendeels de functie van deze ent 
weerspiegelen. De serumconcentraties van bilirubine, gamma GT, alkalische 
fosfatase, gamma glutamyl transferase, alanine aminotransferase activiteit en 
aspartaat aminotransferase activiteit van de getransplanteerde groep zijn 
inderdaad duidelijk lager dan deze van de controlegroep. Deze gegevens 
tonen aan dat in dit model de functionele levertransplant het toxisch effect 
van de cholestase op de natieve lever kan tegenwerken (deel 2.1). 
Om de evolutie en de viabiliteit van de 2 levers na auxillaire 
levertransplantatie snel en herhaaldelijk te kunnen volgen werd voor de 
eerste keer nucleair resonantie-onderzoek gebruikt (MRI). Het onderzoek 
maakte het mogelijk om in eerste instantie de postoperatieve 
levercomplicaties zoals abcessen en parenchymateuze aantastingen van elke 
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individuele lever vroegtijdig te kunnen diagnosticeren. Ten tweede kon men 
via de signaalintensiteit op de T1 gewogen beelden de viabiliteit van elke 
lever beoordelen, waarbij hogere intensiteitsbeelden werden bekomen bij 
betere leverfunctie. Eindelijk maakte deze studie het mogelijk om de 
evolutie van de T1 relaxatietijden van de 2 levers te vergelijken in een 
normale toestand en in geval van levercomplicaties. De finale evolutie van 
de 2 levers kon op deze manier reeds vanaf de eerste postoperatieve week 
voorspeld worden. Deze gevoelige en niet-invasieve meting vergemakkelijkt 
duidelijk de follow-up van de 2 levers na HALTx. MRI is dus een 
veelbelovend werkinstrument in de studie van de functionele competitie 
tussen 2 levers. Prospectieve studies bij de mens zouden op dit vlak zeker 
interessante resultaten kunnen leveren bij de selectie van patiënten lijdend 
aan fulminant of subfulminant leverfalen en voor de bepaling van de 
leverfunctionaliteit na transplantatie of na partiële leverresectie (deel 2.2.). 
In het gebruikte model van HALTx was de portale bloedtoevoer van de 
recipiënt lever volledige geshunt naar de getransplanteerde lever, terwijl de 
viabiliteit van de natieve lever enkel verzekerd werd door bevloeiing via de 
arteria hepatica. Ondanks het feit dat het portaal bloed exclusief naar de 
transplantlever geshunt wordt, blijkt de evolutie van deze ent naar 
regeneratie of atrofie rechtstreeks gebonden aan de graad van de handicap 
aangebracht aan de eigen lever. En een 68% PH, en een galwegen ligatuur 
van de eigen lever is nodig om atrophie van de ent te voorkomen (deel 3.1.). 
Anderzijds, konden wij tonen dat een rearterialisatie van de 
getransplanteerde lever toegevoegd een de portale revascularisatie een 
duidelijk meer uitgesproken stimulatie van de galexcretie na reperfusie met 
zich meebrengt; rearterialisatie gaf ook een hogere DNA synthese, minder 
uitgesproken cytolyse en cholestase. Met rearterialisatie kan men dan ook 
een significant betere entoverleving bekomen. De functionele optimalisatie 
van de ent heeft een rechtstreekse repercussie op de functionele competitie 
tussen de 2 levers (deel 3.2.). 
In het laatste deel van het werk (deel 3.3) konden we aantonen dat in een 
klassiek model van partiële leverresectie een volledige portale derivatie de 
regeneratieve capaciteit van de lever significant verminderd en aldus het 
herstel van de levermassa na leverresectie verhinderd. De spontane arteriële 
compensatie na de portale shunt was onvoldoende om een normale 
regeneratieve respons na partiële hepatectomie te verzekeren. Restitutio van 
het totale leverdebiet via areterialisatie van de portale stomp kon anderzijds, 
merkwaardig genoeg, wel de normale respons herstellen. Deze resultaten 
suggereren dat hoge concentraties van hepatotrofische factoren niet 
essentieel zijn bij de initiële fase van leverregeneratie. 
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In conclusie, het zijn dus niet enkel de portale stimulerende groeifactoren en 
nutritieve elementen, maar het is ook en vooral de algemene functionele 
status van elke lever welke een rechtstreekse invloed heeft op de 
regeneratieve capaciteit van elk individueel organ. Een voldoende debiet, dat 
het weze met arterieel of veneus bloed, via het portaal systeem naar de lever 
moet verzekerd worden om een normale regeneratiechronologie na partiële 
leverresectie te bekomen. 
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RESUME 
Si la transplantation auxiliaire du foie présente des avantages théoriques 
évidents chez les patients souffrants d’insuffisance hépatique aigue ainsi que 
chez les enfants atteints de maladie métabolique congénitale, les resultats 
après ce type de transplantation ne sont pas toujours aussi clairement 
positifs. L’interaction qui a lieu entre le foie donneur et le foie receveur joue 
ici, parmi d’autres, un rôle important. Il est généralement admis que l’apport 
de sang portal contenant les facteurs hormonaux hépatothrophiques 
influence directement le devenir des foies mis en compétition fonctionelle. 
D’autres facteurs tel que l’état physiologique propre de chaque foie 
individuel joue également un rôle dans le devenir des organes mis en 
compétition. Ce fut donc le but du présent travail d’étudier l’influence de 
l’état physiologique et de l’état fonctionel des foies en présence sur la 
balance compétitive interhépatique, et ce, à l’aide du modèle de 
transplantation auxiliaire hétérotopique chez le rat (HALTx). En annexe 
nous avons tenté de réexamimer la controverse au  sujet de la question 
concernant le rôle prépondérant, soit qualitatif, soit quantitatif de l’apport 
portal du sang sur la régénération hépatique après hépatectomie partielle 
standard. 
Afin de suivre dans le modèle de transplantation auxiliair la fonction et la 
viabilité du greffon à l’aide de paramètres biologiques courants, le foie hôte 
fut soumis à un hépatectomie de 68% et une ligature de la voie biliaire 
principale. Ces manipulations chirurgicales du foie hôte sont responsables 
d’une insuffisance hépatique mortelle en l’absence d’un greffon auxiliaire. 
Si la survie des rats est dans ce cas directement dépendant du foie greffé, la 
biologie de l’animal sera un reflet direct de sa fonction. Comparés aux 
groupes contrôles, les groupes transplantées ont des concentrations sériques 
inférieures en bilirubine, gamma GT, fosfatase alkaline, d’activité de gamma 
glutamyl transferase et alanine aminotransferaset. Ces résultats montrent que 
dans ce modèle, un greffon fonctionel peut prévenir l’effet toxique de la 
cholestase du foie hôte. 
Pour l’étude suivante la Résonance Magnétique Nucléaire (RMN) fut utilisé 
pour la première fois afin de suivre la viabilité postopératoire hépatique dans 
le modèle de HALTx. Ce travail a tout d’abord pu mettre en evidence pour 
chaque foie individuel, l’apparition de complications postopératoires tels 
qu’abcès hépatique et nécrose parenchymateuse. Cet examen a montré en 
deuxième lieu que, plus la fonctionalité hépatique est conservée plus le degré 
d’intensité du signal des images pesées en T1 est prononcé. Lévolution de la 
viabilité des 2 foies pouvait ainsi être documentée et comparée à tout 
moment du suivi postopératoire. En comparant l’évolution du temps de 
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relaxation en T1 des 2 foies, l’RMN peut en outre prédire dès la première 
semaine postopératoire le devenir des foies qui resteront sains et ceux qui 
présenteront des complications. L’RMN apparait comme un outil non-invasif 
fort utile pour le suivi de l’évolution des 2 foies après transplantation 
auxiliaire et est prometteur dans l’étude de la compétition fonctionelle 
interhépatique. Des études humaines prospectives en RMN pourraient 
s’avérer dès lors fort intéressantes non seulement pour prédire le devenir 
d’un foie atteint d’hépatite fulminante ou subfulminante mais aussi de 
prognostiquer la viabilité d’un greffon hépatique ou d’un foie restant après 
résection hépatique étendue (partie 2.2.). 
Dans le modèle de HALTx utilisé dans ce travail, l’apport sanguin portal fut 
totalement shunté vers le greffon alors que le foie natif n’était irrigué que par 
l’artère hépatique. Malgré le fait que la totalité du sang portal fut dérivé en 
direction du foie transplanté, l’évolution de celui-ci vers la régénération ou 
l’atrophie dépendait directement du degré d’handicap du foie hôte (partie 
3.1.). Par ailleurs, la réartérialisation du greffon ajouté a sa vascularisation 
portale influence directement et de façon significative la quantité de 
production biliaire posttransplantation et celui de cytolyse et de cholestase 
ainsi que le degré de synthèse d’ADN du foie greffé. La réartérialisation du 
greffon a permis d’obtenir une survie significativement meilleure des 
animaux ainsi traités. La meilleure fonctionalité du foie greffé après 
artérialisation a logiquement un effet direct sur la compétition interhépatique 
(partie 3.2.). 
La dernière partie du travail (partie 3.3.) montre que l’absence totale de 
l’apport de sang portal affecte significativement la régénération du foie et la 
restauration de la masse hépatique après hépatectomie partielle. La 
compensation vasodilatatrice de l’artère hépatique suite à la réduction du 
débit hépatique total après shunt porto-cave est insuffisante pour maintenir 
une régénération normale après hépatectomie partielle. Toutefois, la 
régénération est normalisée si le moignon portal est artérialisé et le débit 
hépatique total restauré à des valeurs équivalentes à celles des groupes 
contrôles. Ces résultats suggèrent que de fortes concentrations de facteurs 
hépatotrofiques ne sont pas indépensable dans la phase initiale de 
régénération hépatique. 
En conclusion, non seulement l’apport portal et son contenu en hormones de 
croissances stimulantes ainsi que d’éléments nutritifs, mais aussi et surtout 
l’état physiologique du foie greffé influence la capacité régénérative des 2 
foies dans le modèle de HALTx. Une quantité suffisante de sang artériel ou 
portal doit être véhiculé par la veine porte aux hepatocytes pour assurer une 
chronologie et intensité normale de la régénération après hépatectomie 
partielle. 
 ABSTRACT 
This work was conducted in rat models to investigate whether the factors other than known 
portal hormonal elements could also influence the inter-liver competition in heterotopic 
auxiliary liver transplantation (HALTx), and whether the quality or the quantity of portal 
supply was more important for hepatic regeneration. 
The results showed that the handicap of a 68% partial hepatectomy (68% PH) plus a common 
bile duct ligation (CBDL) could drastically hamper native liver’s functionality and post-
HALTx animal survival relied solely upon graft’s viability. Thus, the significantly lower 
values of serum biochemistry in the transplanted rats indicated directly that the graft was well 
functioning. 
On a T1 weighted magnetic resonance image, as observed, hepatic complications could be 
depicted individually in the coexisting two livers and hepatic viability could be assessed by its 
signal intensity. The healthy grafts could be distinguished from those that later developed 
complications by a significant decrease in T1 relaxation times at an early post-transplant stage. 
Despite with proper portal supply, the engrafted liver would atrophy if the native liver was 
handicapped with a 68% PH alone, whereas graft regeneration was assured by a more severe 
handicap (adding a CBDL). Furthermore, when the graft’s physiological status was improved 
through re-establishing its arterial supply, it had not only a better early function (immediate 
bile flow rate and bilirubin excretion) and less biliary complications (cytolysis and 
cholestasis), but also more pronounced liver regeneration (DNA synthesis rate and graft 
growth) compared with that of control group. 
Complete absence of portal supply to a partial resected liver caused a marked inhibition of 
early regenerative response and liver growth. When an equivalent amount of portal blood 
inflow was re-established by arterialising the portal stump, DNA synthesis rate and liver 
growth could be sustained at a level comparable to that of control rats. 
These data emphasize that, besides portal supply, a change of the physiological condition of 
each individual liver does affect the balance of the inter-liver competition after HALTx. 
Rather than a high concentration of hormonal factors, the presence of sufficient blood flow in 
the portal tract, of either venous or arterial origin, appears a prerequisite to maintain a normal 
chronology and intensity of hepatic regeneration. 
